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ABSTRACT 
 Patients with critical-size bone defects, as a result of trauma, congenital malformations or 
tumor resections, generally have limited healing without clinical intervention. The autograft is 
the current standard of care for repair of these defects due to capacity for osteointegration and 
immunological compatibility. However, potential limitations, such as donor site morbidity, have 
motivated the development of alternative autologous approaches for the treatment of these 
defects. Materials used in tissue engineering, such as scaffolds, growth factors and adult stem 
cells, can be derived from patient blood and adipose tissue and are potential autologous 
therapeutic options. This dissertation investigates a prospective procedure to improve 
craniofacial bone healing using fibrin scaffolds and platelet rich plasma from patient blood, and 
adipose-derived stem cells from liposuction. The objectives of these studies are to evaluate the 
effects of fibrin scaffolds and platelet-rich plasma on adipose-derived stem cells and their ability 
to heal critical-size bone defects in a porcine animal model. 
 During coagulation of whole blood, fibrin scaffolds were modified using treatments to 
reduce red blood cell density and porosity or increase concentrations of calcium and phosphate 
ions. Platelet-rich plasma was collected using an anticoagulant with subsequent centrifugations 
to acquire the fraction of plasma with high concentrations of growth factor-releasing platelets. 
Both fibrin scaffolds and platelet rich plasma were cultured with adipose-derived stem cells to 
determine proliferation, migration, and osteogenic differentiation potential. Autologous adipose-
derived stem cells, platelet-rich plasma, and fibrin scaffolds were injected into critical-size 
defects in the porcine mandible. Analysis of bone healing after 8 weeks indicated higher bone 
mineral density and bone volume fraction compared to untreated controls for all three treatments 
using ASCs. Addition of both platelet rich plasma and fibrin scaffolds to autologous ASCs from 
liposuction improved bone volume fraction of critical-size defects. Based on these results, 
addition of either platelet-rich plasma or calcium phosphate-fibrin composite scaffolds to 
autologous adipose-derived stem cells are recommended to for further improvement in healing of 
critical-sized bone defects.  
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CHAPTER 1                                                                                                      
INTRODUCTION 
1.1 Clinical Rationale 
1.1.1 Current Practices 
Delayed or non-union bone defects do not heal spontaneously without clinical 
intervention and are the result of numerous clinical conditions, including tumor resections, 
congenital abnormalities and traumatic injuries [1]. About 500,000 patients in the United States 
are affected annually, an estimated 5-10% of all bone fractures [2]. While the mechanism of 
delayed or non-union is under investigation, one primary factor is defect size. A non-union, 
defined as less than 10% bone regeneration, occurs at a critical size, generally when the length of 
the defect is approximately 1.5-2 times the thickness of the damaged bone [3]. Several factors 
likely play a role in the determination of the critical size, including surrounding blood supply, 
intactness of periosteum, biomechanical fixation, age, and presence of co-morbidities such as 
diabetes [4].  
Currently, the gold standard for treatment is the autograft, where bone is harvested from a 
donor site in the same patient (usually iliac crest, rib, or fibula) and is shaped by the surgeon to 
fill the defect. This approach confers many advantages in terms of patient outcomes, including 
superior immunological compatibility and low risk of graft failure. However, complications 
occur in up to 30% of all cases primarily due to the second surgical site, including pain in the 
harvested area, as well as increased blood loss [5]. The drawbacks of donor site morbidity and 
limited tissue supply have prompted development of alternative methods which can overcome 
these disadvantages, especially for cases in which a large amount of grafted bone is required. 
One currently used alternative is the allograft, which utilizes bone from a human donor. 
While removing the problems of the second surgery site, allografts generally have limited 
promotion of bone growth and have the potential for immune rejection leading to graft failure 
[6]. In addition, mechanical weakening can occur due to the sterilization procedure using gamma 
irradiation or during packaging or storage by freeze drying. And while small, a theoretical risk of 
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disease transmission remains [7,8]. Therefore, allografts are typically utilized when a patient is 
not a candidate for autografting. 
Other alternatives include the use of xenografts, typically decellularized bovine bone. 
While generally available and inexpensive, xenografts are immunologically incompatible and 
may require the use of immunosuppressant drugs, which lower resistance to infection [9]. For 
patients who would have limited success with bone grafts, metallic implants can be used to 
restore form and function and improve quality of life. Currently, alloys of cobalt chromium or 
titanium are most widely used. However, these metals are more than ten times stiffer than bone 
causing tissue at the implant interface to be shielded from normal stresses, which can result in 
resorption over time, leading to implant failure [10]. Though immunologically less problematic, 
metallic implants cannot repair or remodel and have limited integration with surrounding bone, 
which serves to limit their useful lifetime before revision surgery is required.  
The current state of the art for treating delayed and non-union defects involves tradeoffs. 
To obtain the generally superior results of the autograft, a second surgical site is required. In 
order to eliminate this site, allografts or xenografts have issues with immunological 
compatibility. To improve these issues, metallic implants have limited integration with 
surrounding bone [10]. The ideal bone graft would be biocompatible without requiring a second 
surgical site. Potential bone grafting substitutes generally require low risk-benefit ratios for 
widespread clinical use. Therefore, complications of the bone grafting procedures and metallic 
implants have prompted investigation into alternative methods, such as the tissue engineering 
approach.  
1.1.2 Bone Tissue Engineering 
The fields of tissue engineering and regenerative medicine aim to interact with host 
tissues to stimulate regeneration and reduce formation of scar tissue [11]. Newly regenerated 
bone would retain its ability to repair and remodel itself over the patient’s lifetime, potentially 
achieving similar levels of integration as an autograft without requiring a second surgical site. 
The tissue engineering triad involves the use of scaffolds, growth factors, and cells [12]. 
Scaffolds provide an intermediate surface for cells to attach and guide the process of tissue 
formation. Over time, these scaffolds are resorbed to make space for newly forming tissue. 
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Growth factors provide instructions for migration, proliferation, and differentiation of cells to 
form bone and other important support structures such as vascular networks. The sources of 
these essential elements are important in determining the outcome of any proposed therapy. 
Currently, most tissue engineering strategies utilize synthetic scaffolds, recombinant growth 
factors, and/or culture-expanded stem cells.  
Tissue engineering strategies vary depending on the amount of cell culture work needed 
[13]. The first approach, in situ (in place), utilizes scaffolds and growth factors and relies on 
interaction with the host tissue microenvironment. The second approach, ex vivo (outside the 
living), adds cells isolated from a patient or donor and then re-inserted into the patient. The third 
approach, in vitro (on glass), produces most tissue in a laboratory bioreactor before implantation. 
This dissertation focuses on the second approach, ex vivo bone tissue engineering. 
As a tissue, bone is a composite material of collagen I reinforced with hydroxyapatite 
crystals. Following a bone fracture, an initial fibrin blood clot forms and the inflammatory 
process is initiated to degrade necrotic tissue. Mesenchymal stem cells (MSCs) from the marrow 
stroma, periosteum and surrounding tissues migrate to the wound site and proliferate to form a 
soft, collagenous callus, which is invaded by new blood vessels. On the order of weeks, new 
bone matrix will be secreted for calcification into a hard callus which is slowly remodeled back 
to the original organization [14]. Compared to other tissues, bone has evolved a high capacity for 
regeneration, but its effectiveness is still limited by defect size. Migrating MSC number and 
activity, blood vessel invasion, and callus calcification are all potential limiting factors, which 
are current targets for tissue engineering strategies [15,16] 
An array of scaffolding materials has been developed for the purpose of bone tissue 
engineering. These include natural polymers such as collagen, hyaluronic acid and fibrin, as well 
as synthetic polymers such as poly-glycolic acid (PGA), poly-lactic acid (PLA) and its 
copolymer (PLGA), and polycaprolactone (PCL) among others [17]. Ceramics composed of 
calcium phosphates and calcium sulfates have also been used. Each of these materials has their 
respective strengths and weaknesses in terms of strength, degradation speed and products, 
biocompatibility, and ease of processing. Depending on the application, anatomical bone 
location, and loading requirements, each material has potential to be used for the repair of bone 
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defects. The natural polymer, fibrin, a primary constituent of blood clots, is the focus of this 
dissertation. 
The principal growth factors involved in bone regeneration include fibroblast growth 
factor (FGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), 
transforming growth factor (TGF), and the bone morphogenetic proteins (BMP), among others 
[18]. The sources of these growth factors include platelets, white blood cells, surrounding bone, 
and/or recombinant proteins added therapeutically. Each growth factor plays overlapping roles in 
the process of bone formation, and one prevailing notion in tissue engineering is that increasing 
the concentration by the correct amount, location and time course of one or more of these growth 
factors may enhance the healing process. While each growth factor family varies in its amino 
acid sequence and intracellular pathways activated, many activate serine threonine kinase 
receptors and are biologically active as dimers (PDGF, TGF, BMP).  
In particular, PDGF and FGF play a key initiatory role, increasing cellular migration 
towards the wound and proliferation at its site [19]. FGF and VEGF are potent stimulators of 
proliferation and angiogenesis to build vascular support networks. TGFs and BMPs have 
overlapping roles in proliferation and are essential to begin the cascade toward the eventual 
upregulation of the transcription factors Runx2, and Osterix. This results in the upregulation of 
genes which are markers of osteoblasts, including collagen I, alkaline phosphatase, osteocalcin 
and osteopontin, resulting in the synthesis of collagen and the enzymes which cause its eventual 
mineralization into bone [20].   
Cells used in bone tissue engineering tend to focus on adult stem cells for their ease of 
isolation and ability to expand in culture [21]. Adult stem cells from different tissue sources, 
such as bone marrow, fat, periosteum, and teeth have been effectively used in bone tissue 
engineering. Embryonic/induced pluripotent stem cells have not been as widely used due to 
possibility of teratoma formation, immune rejection, and/or ethical concerns. Differentiated 
osteoblasts have potential but are also less widely used due to more difficult isolation and 
reduced proliferation. 
While both autografts and tissue engineering are the future of bone defect repair, it is 
possible that a hybrid, autologous tissue engineering approach, where cells, scaffolds and growth 
factors are acquired from the patient, may capitalize on the advantages of each technique. An 
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autologous tissue engineering method, as detailed in this dissertation, has the potential to 
maintain similar performance and compatibility to an autograft without requiring harvesting of 
patient bone, avoiding its associated complications.  
1.2 Fibrin Scaffolds 
1.2.1 Background and Biology 
One factor less-studied in the bone fracture healing process is the natural polymer, fibrin, 
which is a primary component of blood clots. Blood contains constituents essential for the 
wound healing process, including coagulation cascade enzymes and fibrinogen. In fibrin’s native 
form, it exists as a soluble monomer, fibrinogen, which circulates through the cardiovascular 
system. Upon activation through damage-induced exposure to collagen or other mechanisms, 
fibrinogen converts to insoluble fibrin under the control of a series of enzymatic steps of the 
coagulation cascade [22]. These polymerizing fibers cross-link together to form a stiff clot able 
to limit blood loss and act as a scaffold in the wound repair process.  
Fibrinogen is a glycoprotein produced by the liver, 340 kDa in size and circulates at a 
concentration of 1.5-4.0 g/L (7 µM) in blood. Fibrinogen is composed of three peptide chains 
linked by disulfide bonds (α, β, γ) for which coiled α-helices predominate in their secondary 
structures [23]. These coiled-coils are a major source of elasticity for the polymer allowing for 
stretching 2-3 times the original length [24]. Two N-terminals associate (E domain), forming a 
hexamer with the C-terminals (D domain) left externally exposed as recognition sites. Bonding 
between N-terminals is on the α-chain, but two non-reacting peptides (fibrinopeptide B) are 
maintained on the β-chain, which aids in maintaining solubility. 
Following activation through the intrinsic and/or extrinsic pathways, a cascading series of 
enzymes, in which the preceding enzyme acts as a catalyst for activation of the next, result in the 
eventual activation of Factor X [25]. This enzyme cleaves and exposes cryptic sites on the 
zymogen prothrombin, converting to thrombin, a serine protease capable of interacting with 
fibrin. Thrombin’s activated protease sites cleave fibrinopeptide B from both β-chains, allowing 
for the formation of insoluble protofibrils. Lateral bonding of protofibrils between similar 
domains result in the formation of fibrin fibers. These insoluble fibers intertwine and form a 
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three-dimensional fiber network , trapping red blood cells and platelets to rapidly form a soft 
blood clot. On the order of minutes, another enzyme in the coagulation cascade, the 
transglutaminase Factor XIII, links N-terminal domains with lateral C-terminal domains, serving 
to cross-link and stiffen the fibrin gel [26]. 
The completed fibrin gel is viscoelastic and approximately 30 kPa in stiffness [27]. 
Several factors during coagulation play a role in the properties of the gel, including ion and 
fibrinogen concentrations, fiber thickness and density, and branch point density [28,29]. Charged 
inter-helical interactions between chains allow for positively-charged hydrogen ions, among 
others, to interact, serving to increase resistance to stretch by electrostatic repulsion, which 
increases stiffness of the gel. There is a general inverse relationship between fiber thickness and 
density, depending primarily upon the ratio of fibrinogen to thrombin during polymerization. 
Because individual fibers are highly elastic, fibrin gels with thick fibers and low density will 
have low stiffness. Fibers at high density are highly entangled and provide more points of 
resistance to movement and a stiffening effect. The number of potential branch points also 
increases, further stiffening the gel. 
However, while fibrin provides the initial wound microenvironment for bone fracture 
repair, some aspects of fibrin clots may present challenges for the success of potential ASC 
therapies. Two possible limitations of fibrin include its comparatively low stiffness and ion 
concentrations [30]. For example, trabecular bone is approximately four orders of magnitude 
stiffer than fibrin [31]. Scaffold stiffness on the order of trabecular bone and presence of calcium 
and phosphate ions have both been shown to increase osteoblast differentiation [32]. Therefore, 
modifications which can stiffen fibrin and reasonably increase its local ion concentrations may 
result in improved outcomes for ASC therapy for bone defects.  
Potential methods to increase blood clot stiffness include reduction of red blood cells and 
porosity, reducing pH, and addition of stiff granules to form a composite. Reducing pH increases 
protonation of residues which results in more charged inter-helical interactions. Forming 
composites with stiffer, insoluble materials, such as calcium phosphates, could result in more 
balanced properties, similar to the collagen-hydroxyapatite composite of bone [33]. Highly-
deformable red blood cells, which are designed to flexibly move through capillaries, decrease the 
stiffness of blood clots due to their low stiffness (order of 10 Pa) [34]. Reducing the number and 
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intactness of red blood cells in a blood clot may increase stiffness. In addition, cross-linking 
density of fibrin is below its maximum [26]. Finally, reducing porous empty space between 
fibers significantly increases stiffness [35]. In summary, fibrin is a flexible hydrogel whose 
polymerization conditions determine its structure and properties which may be modified for 
improved bone defect healing. 
1.2.2 Therapeutic Use 
 Blood may present an alternative source of autologous materials for use in craniofacial 
bone defect repair. Compared to bone, blood is more accessible, more plentiful in supply, and 
results in less structural deformity following its collection by blood draws. Therapeutically, 
clotted blood and its derivatives, such as fibrin glue and fibrin sealant, have been recognized for 
their useful properties of hemostasis and tissue adhesion since the 1980s and have been widely 
used to reduce blood loss during and bleeding after surgical procedures [36]. Fibrin sealants also 
can be utilized as carriers for the release of drugs, such as growth factors and antibiotics due to 
their biocompatibility and resorption on the order of weeks. 
In the United States, sources have historically been autologous from the patient due to the 
risk of viral contamination, though virally-inactivated products from donors have now been 
approved for clinical use [37]. Fibrin sealants/glues vary in formulation but consist of a 
concentrated solution of fibrinogen mixed with thrombin (human or bovine) and calcium 
chloride during the operation. Administration can be through syringe injection or sprayed at the 
wound site. Fibrin sealants are generally tolerated well and have limited side effects, making 
them candidate biomaterials for bone defect repair.  
Despite its demonstrated effectiveness in the repair of soft connective tissue defects, the 
use of fibrin to promote healing of hard bone tissue defects is generally controversial. Some 
studies report reductions in bone formation [38,39] while others report no effect when treated 
with fibrin sealant alone. Clinical usage of fibrin sealants for bone applications has been limited 
and has focused primarily upon its hemostatic properties. One successful orthopedic application 
of fibrin sealants has been in total knee arthroplasty and have been shown to reduce blood loss 
during surgery [40]. 
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General surgical techniques such as suturing aim to limit empty space in the wound, as 
the subsequently large internal blood clots tend to result in scar tissue formation. Fibrin’s density 
may impede cell infiltration and slow the wound healing response. In contrast, fibrin is generally 
thought to support wound healing through the promotion of angiogenesis, cell proliferation and 
attachment [41]. Therefore, when adult stem cells are combined with coagulating blood, 
bypassing the requirement of cell invasion, the results may be more positive in terms of bone 
growth. 
 Combining fibrin scaffolds with calcium phosphate granules to form a composite is a 
more recent development and has been demonstrated to improve bone formation in defects and 
ectopic sites [33,42]. Calcium phosphate ceramics such as hydroxyapatite and tri-calcium 
phosphate have been used as bone graft and filling substitutes since the 1980s. Similar to the 
ceramic portion of native bone, calcium phosphate granules may provide calcium and phosphate 
ions and local stiffness on the scale of native bone, which has been demonstrated to promote 
osteoblast differentiation [43].  
However, calcium phosphate granules alone, while osteoconductive, are difficult to 
handle and are mechanically unstable in large defects, which can be amended by mixing the 
granules in polymerizing fibrin to immobilize granules to the implantation site. Clinical studies 
of fibrin-calcium phosphate composites have been limited to large animal models and individual 
surgical case reports, but generally have demonstrated improved defect filling in calvarial defects 
[44]. In summary, fibrin sealants and glues represent an excellent surgical tool for the promotion 
of hemostasis, tissue adhesion, and soft tissue defect healing. Forming a composite with calcium 
phosphate granules may result in improved hard tissue defect healing as well.  
1.3 Platelet-Rich Plasma 
1.3.1 Background and Biology 
Bone regeneration is dependent upon various signals, including growth factor 
concentration gradients and mechanical stresses and strains [45]. One cell type in particular, the 
platelet, plays a key initiatory role in the wound healing process as an important source of 
growth factors directing the initial healing response. These small, circulating, anucleate cells 
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store high densities of growth factors within their cytoplasmic granules [46]. Platelets originate 
from within the bone marrow as portions of exocytosed cytoplasm from megakaryocytes and 
circulate at a concentration of 200,000 per µL blood. Within minutes of activation at the site of a 
wound, platelets begin to aggregate to form a sticky platelet plug for initial cessation of bleeding, 
as well as release factors for the promotion of vasoconstriction, inflammation, and initiation of 
the coagulation cascade [47]. One primary pathway of platelet activation is damage-induced 
exposure to collagen and von Willebrand factor, which is not normally present in intact blood 
vessels.  
Following activation from the wound microenvironment, platelets degranulate, releasing 
significant quantities of factors for the initiation of inflammation and the healing response. Dense 
granules, containing mostly inflammatory factors such as adenosine diphosphate (ADP), act to 
regulate platelet activity by positive feedback through recruitment of additional platelets to the 
site of the wound and release of their contents. In addition, arachidonic acid is converted to 
thromboxane A2, a potent initiator of inflammation and white blood cell migration.  Previously 
smooth and spheroid in shape, degranulation induces surface and morphological changes causing 
platelets to be sticky and irregular, allowing them to clump together as a plug. Many enzymatic 
conversions of the coagulation cascade occur on surfaces of platelets [48].  
Upon activation, platelets also release the contents of their α-granules, containing mostly 
growth factors [46]. As relatively small signaling proteins, growth factors play an essential role 
for bone fracture healing and include platelet-derived growth factor (PDGF) which is a potent 
mitogen, fibroblast growth factor (FGF) which is important for vasculogenesis, and transforming 
growth factor-β (TGF-β) which induces cell differentiation into collagen-producing cell types, 
among others. The only growth factor family not generally present in platelets is the bone 
morphogenetic proteins (BMPs), which are found in native bone and released following damage 
and resorption. 
PDGF concentration increases over 4-fold following platelet activation and is a potent 
stimulator of chemotaxis and proliferation. It consists of two isoforms (A or B) and is active as a 
heterodimer (AB) or homodimer (AA or BB) linked by disulfide bonds. Tyrosine kinase 
membrane receptors are activated in target cells, resulting in intracellular signaling through the 
PI3K pathway, of which calcium ions are essential. Its primary intracellular effect on gene 
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transcription in the nucleus is to allow cells to skip the G1 regulatory checkpoint in mitosis to 
promote rapid cell division [49]. 
FGFs are a family of growth factors which play important roles in embryonic 
development, wound healing and angiogenesis. In addition, they have been shown to increase the 
rate of adipose-derived stem cell proliferation [50]. FGFs act through FGF receptors, a type of 
tyrosine kinase receptor. In particular, FGF-2 (basic FGF) is potent mitogen of mesodermal 
tissues such as bone and is involved in patterning of limb development. FGF-2 is a key 
stimulator of vasculogenesis during bone healing. 
The TGF-β superfamily, which includes the BMPs and TGF-β among others, originates 
from higher molecular weight precursors and are activated by proteolytic enzymes. On target 
cells such as mesenchymal stem cells, they act on serine/threonine kinase membrane receptors. 
Intracellular signaling is through the Smad pathway for many family members, leading to 
eventual alteration of gene expression in the cell nucleus [20]. In particular, TGF-β1 is the most 
abundant growth factor in human bone and plays a key role in the initial embryonic development 
and patterning of the skeleton. Whether the source is native bone or degranulation, platelets 
possess key proteolytic enzymes for the activation of TGF-β1, which is a potent growth factor 
for the chemotaxis, proliferation, and differentiation of mesenchymal stem cells [51]. This 
growth factor concentration increases 3.5-fold following platelet activation and degranulation. 
Together, these growth factors make platelet activation and growth factor release important for 
the initiation of the wound healing.  
Following a fracture, a cascade of signaling molecules directs the bone’s eventual 
regeneration. Due to its highly vascularized nature, significant hematoma formation and 
inflammation develops, which is initiated by platelet release of inflammatory mediators. 
Neutrophils and macrophages are then recruited for debridement of ischemic tissue and release 
of inflammatory cytokines to enlist more white blood cells. By the first 24 hours, mesenchymal 
stem cells are recruited primarily through chemotaxis toward gradients of PDGF and TGF-β 
released by platelets [52]. The process of angiogenesis is initiated by the third day post-fracture 
with FGF and vascular endothelial growth factor as the primary growth factors coordinating the 
response [53].  
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1.3.2 Therapeutic Use 
Therapeutically, platelets have been utilized as a readily accessible source of growth 
factors through the use of platelet-rich plasma (PRP), in which autologous blood is collected 
with anticoagulant (sodium citrate) and spun in a centrifuge [54]. PRP contains a high density of 
platelets and is acquired from the lowest fraction of plasma and upper fraction of the white blood 
cell-containing buffy coat. The PRP fraction is isolated and stimulators of platelet activation 
(thrombin and/or calcium chloride) are added to inactivate residual anticoagulant and release 
growth factors through platelet degranulation. 
Autologous PRP was first used in 1987 by Ferrari to avoid excessive blood product 
transfusions [55]. PRP has since been used for a range of therapies, including orthopedic, dental, 
and neurosurgical applications, among others [56]. Administration is generally considered safe, 
with a low risk of infection occurring when sterility precautions are not sufficiently followed. 
Typically, 30-60 mL of venous blood is withdrawn, then an initial centrifugation step is 
performed to remove red blood cells and obtain plasma. A second centrifugation at a higher 
speed separates platelet-poor and platelet-rich plasma fractions to obtain a total of 3-6 mL of 
PRP. 
Improvement of the rate of bone fracture healing has been demonstrated through the use 
of PRP in preclinical animal models and case reports, while clinical trials have yet to be 
performed [57,58]. The mechanism of healing is most likely due to increased growth factor 
concentrations at the wound site. While PRP appears to be efficacious in promoting wound 
healing, clinical outcomes of total effectiveness have been mixed, due primarily to the strong 
pro-inflammatory component of platelet-released factors [59]. Therefore, clinical use of platelet-
rich plasma may require balancing with anti-inflammatory drugs. Or, anti-inflammatory cytokine 
release, such as from adipose-derived stem cells [60], may provide inflammatory suppression to 
remedy this potential limitation. 
Other current limitations of PRP therapy are variability between methods for its 
collection and between patients. Currently, two systems are approved for PRP collection in the 
United States, but substantial variability remains in the clinical protocols used, including amount 
of blood extracted, centrifugation speed and time, fractions isolated, as well as stimulants of 
platelet activation. These differences have resulted in an assortment of platelet concentrations 
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used clinically (3-8 fold increase above baseline), which may explain some of the mixed results. 
In addition, the thrombin commonly used to activate platelets uses bovine sources, which may 
further exacerbate inflammation. Therefore, protocols for large-scale clinical use will require 
standardization to improve treatment consistency. 
Compared to growth factors obtained from recombinant (bacterial or mammalian cell) 
sources, growth factors from PRP are lower in cost and allow for the administration of multiple 
growth factors simultaneously, a technique which is more difficult using recombinant sources. 
No studies have documented PRP to promote tumor growth, while using recombinant growth 
factors at high concentrations may present an increased risk [61]. The key tradeoffs are reduced 
control of dosage and side effects which stem from inflammation. Despite current limitations, 
PRP therapy represents an autologous alternative to recombinant growth factors. The general 
consensus for PRP indicates a promising potential therapy to promote enhanced bone healing, 
but further study in clinical trials is needed before widespread adoption.  
1.4 Adipose-Derived Stem Cells 
1.4.1 Background and Biology 
Mesenchymal stem cells (MSCs) descend from embryological mesoderm and are defined 
to retain into adulthood the capacity to differentiate into cells which produce and maintain the 
connective tissues, such as bone, adipose, muscle, cartilage, and marrow stroma, among others 
[62]. MSCs are capable of self-renewal primarily through asymmetric cell division, in which one 
daughter cell differentiates into the desired cell type while the other remains an undifferentiated 
clone and capable of self-renewal. These adult stem cells are isolated for primary culture through 
tissue biopsy and digestion using an enzyme such as collagenase or trypsin. Following 
centrifugation, the subsequent stromal-vascular fraction is plated onto tissue culture plastic 
(irradiated polystyrene), and the fraction of cells which attach and form colonies originating from 
a single cell are defined to be mesenchymal stem cells. The gold standard to prove stemness 
would be to isolate a single colony and then differentiate into multiple lineages such as 
osteogenic, adipogenic, and chondrogenic, among others using lineage-specific induction factors. 
However, plastic adherence is typically sufficient in practice, resulting in a cell population which 
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is heterogeneous and fibroblast-like in nature. MSCs are capable of expansion of over one 
billion-fold in culture without loss of multipotency [63]. Over multiple passages, the population 
increases in homogeneity as more rapidly proliferating cell types predominate, but retain their 
differentiation capacity. 
In vivo, MSCs are less well-defined, but perictyes are one population of cells, residing 
outside of capillaries, which share many characteristics with MSCs [64,65]. Both cell types are 
angiogenic, aiding in the stabilization of blood vessels, as well as anti-apoptotic, reducing the 
field of injury and reducing scar tissue formation. Pericytes and MSCs are also generally anti-
inflammatory through the release of cytokines such as interferon-gamma (IFN-γ), tumor necrosis 
factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-10 (IL-10) [66]. These cytokines 
primarily act through suppression of helper T-cells, reducing length of inflammation and severity 
post-injury. During a bone fracture, MSC proliferation and cytokine production becomes a major 
factor in the substantial decrease in inflammation by the third day. 
Historically, MSCs were first isolated from bone marrow. Bone marrow-derived stem 
cells (BMSCs) remain the gold standard clinically for their well-developed protocols for marrow 
biopsy, expansion, and osteogenic differentiation. However, limitations using bone marrow as a 
source for MSCs include low tissue volumes per donor and low density of cells per volume of 
bone marrow. In addition, this density appears to decline with age as red marrow slowly converts 
to yellow, more fatty marrow [67]. Biopsy procedures also result in significant pain for an 
already clinically valuable material used in bone marrow transplants for the treatment of 
hematopoietic disorders. Therefore, most strategies involving BMSCs involve expansion in 
culture to compensate for low cell numbers, a significant obstacle for widespread clinical use.  
In comparison, adipose-derived stem cells (ASCs) have been more recently isolated, but 
retain several similarities to BMSCs, including plastic adherence, cell morphology, and 
capability to undergo osteogenic differentiation [68]. In addition, they share a 97% correlation in 
transcriptome during osteogenic differentiation and a 90% similarity in expression of cell surface 
markers [69]. Though some differences are present, such as response to some growth factors and 
morphology of osteogenesis in vitro, ASCs may be a suitable substitute cell population for 
BMSCs for bone tissue engineering applications. However, suitable preclinical studies in large 
animal models would aid in improving potential clinical protocols. 
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The isolation of ASCs presents key advantages. Adipose tissue is typically abundant in 
the body, and its anatomically superficial location improves accessibility by liposuction or 
lipectomy. An estimated 1 out of 10,000 nucleated cells in adipose tissue is estimated to be an 
ASC, which does not appear to change significantly with age, a significantly higher density (10-
fold) than BMSCs. In addition, 2-3 L of lipoaspirate may be collected under local anesthesia per 
liposuction procedure, which would otherwise be discarded [70]. Compared to less than 300 mL 
for bone marrow biopsy, a higher density of cells and capability of collecting more tissue 
provides an opportunity for collecting clinically relevant numbers of ASCs without the need of 
expansion in culture. This creates an opportunity to utilize ASCs as an autologous therapy 
without requiring specialized culturing facilities as is generally required for BMSCs. 
1.4.2 Therapeutic Use 
Past advances in the isolation, characterization, and differentiation of these relatively rare 
adult stem cell populations have opened up new opportunities for the treatment of a wide range 
of clinical conditions. Due to their properties of promoting vascularization, modulating 
inflammation, and promoting tissue formation [71], ASCs have been investigated for treating 
muscular dystrophy, diabetes, autoimmune disorders, and graft versus host disease, among others 
[72,73]. However, this review will focus on the use of ASCs to promote healing of bone defects. 
While precise mechanisms of action for ASC healing of bone defects are unknown, 
vascular infusion or direct injection of undifferentiated ASCs have the potential to remedy 
limiting factors of critical-size bone defects by migration, proliferation, and differentiation into 
the proper cell types required by the regenerating tissue. Other effects include their generally 
anti-inflammatory cytokine release profile and recruitment of surrounding cells by secretion of 
growth factors and cytokines [74]. At the site of a bone defect, ASCs may modulate the 
inflammatory response, recruit surrounding cells, and/or differentiate into osteoblasts to directly 
build new bone.  
Several options are available regarding the source and method of administration of ASCs. 
Cross-tissue autologous cell transplants are one method in which the patient donates tissue, such 
as fat by liposuction, for isolation of ASCs to be received by the patient’s bone. ASCs can be 
administered intra-operatively, expanded in culture prior to treatment, or allowed to form bone at 
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an ectopic site before engraftment at the wound site. Currently, ASCs from liposuction are in use 
clinically for adipose tissue grafts and other procedures involving fat transfer, showing 
improvement in graft vascularization and integration [75]. Intra-operative use of ASCs for 
calvarial bone defects has shown improved bone formation in case studies, and has potential for 
widespread use if safety and efficacy can be established [76]. In one clinical case, maxillary 
reconstruction was successfully accomplished by culturing ASCs using good manufacturing 
practice (GMP) methods along with tri-calcium phosphate and BMP-2 and insertion in an 
ectopic site before transplantation [77]. 
Another option in ASC therapy lies in the use of allogenic cells. There are an estimated 1 
million liposuction procedures worldwide, and most of the resulting lipoaspirate is currently 
discarded [70]. MSCs do not express B7 or CD40, which are key cell surface markers necessary 
to activate T-cells to stimulate the host-transplant rejection response [78]. The immune-
privileged nature of ASCs provides donor flexibility for an abundant and accessible tissue 
source. In a porcine mandible animal model, infusion of allogenic ASCs either intravascularly or 
directly injected resulted in an increased rate of bone formation [79]. Addition of BMP-2 and 
ASCs in a fibrin matrix in the rat femur reduced callus volume with no loss of bone formation 
compared to administration of BMP-2 alone [80]. Human ASCs genetically modified to 
overexpress BMP-2 were injected into critical-size rat femoral defects and found to improve 
healing [81].  
A current therapeutic question for ASC therapy for bone defects is whether or not an 
inductive factor is required before administration or whether the wound microenvironment 
provides sufficient induction. Most studies favor using growth factor administration which 
directly stimulates osteogenic differentiation, such as BMP-2, along with ASC infusion. One 
assumption of this approach is that administered cells produce the majority of the newly formed 
bone tissue. The results of this combination have been mixed, with some evidence suggesting 
ASCs do not directly respond to some growth factors [82]. Growth factor administration which 
favors proliferation of undifferentiated ASCs in vivo is a currently less utilized approach which 
may capitalize on other therapeutic benefits, such as anti-inflammatory and angiogenic properties 
while maintaining capacity for osteogenic differentiation.  
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In summary, autologous ASCs present advantages of biocompatibility and reduced 
complications compared to harvesting of patient bone for autografting. An autologous tissue 
engineering approach utilizing ASCs from lipoaspirate may improve the healing outcomes of 
critical-size bone defects. Combining blood-derived growth factors and fibrin scaffolds with 
adult stem cells derived from fat comprises a construct which is consistent with the autologous 
tissue engineering paradigm and may result in further improvements in bone healing. 
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CHAPTER 2                                                                                                                                 
IN VITRO OSTEOGENESIS ON FIBRIN SCAFFOLDS  
2.1 Overview 
 This chapter covers the process of collecting modified fibrin scaffolds, analysis of their 
mechanical properties, and culture with ASCs for osteogenic differentiation. The primary aim 
was to develop a fibrin scaffold for optimum in vitro osteogenic differentiation of porcine ASCs. 
Fibrin scaffolds physically and chemically modified to be stiffer or have a higher concentration 
of calcium and phosphate ions were hypothesized to enhance osteogenic differentiation 
compared to control fibrin scaffolds. Treatments during coagulation resulted in 6 scaffold types 
for comparison: whole blood controls, red blood cell lysis buffer, calcium chloride, calcium 
hydrogen phosphate, vacuum, and mechanical compression. Fibrin scaffolds treated with red 
blood cell lysis buffer and calcium hydrogen phosphate were determined to be stiffer compared 
to untreated controls. In addition, treatment with calcium phosphate was found to accelerate 
coagulation. Osteogenic differentiation was enhanced on scaffolds treated with calcium chloride 
and calcium hydrogen phosphate. It is likely these results are explained in part by ASC 
attachment and fibrin polymerization during coagulation. Based on these results, calcium 
phosphate was selected as the method to modify fibrin for the in vivo study (Chapter 4). 
2.2 Methods 
2.2.1 Blood Collection and Fibrin Modification 
Whole blood was collected in sterile 1-liter containers from 6 pigs and allowed to clot 
with different treatments, which included solutions (2.4 and 7.2 mM) of calcium chloride (CaCl2, 
Sigma C7902, St. Louis, MO), or calcium hydrogen phosphate (CaHPO4, Mallinckrodt #4272, 
Hazelwood, MO), a precursor to completed bone mineral (hydroxyapatite, Ca5(PO4)3OH). 
Highly flexible red blood cells (RBCs) were removed osmotically with red blood cell lysis buffer 
(25% or 50% to blood, 8.3 g/L ammonium chloride, Sigma R7757). To reduce porosity, samples 
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were mechanically compressed under pressure (200 MPa) in a syringe using free weights or 
placed under vacuum (130 kPa) during coagulation. Samples were stored at -20°C [1]. 
2.2.2 Coagulation Time 
 During whole blood collection, samples from 4 pigs were timed to determine the rate of 
coagulation under various treatments. Blood was collected in 50 mL centrifuge tubes and 
agitated manually. Timing began upon collection in an individual tube and ended upon cessation 
of motion during tube rocking [2]. Coagulation time was normalized to untreated whole blood 
for each individual pig.   
2.2.3 In Vitro Degradation 
Samples were cut into approximately 2 gram sections and pressed flat onto 10 cm2 tissue 
culture plates with 5 mL of Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma D5648) and 
varying concentrations (0, 1, 5, 10%) of fetal bovine serum (FBS, BenchMark, Gemini Bio-
Products, Sacramento, CA) [3]. At weekly intervals, samples were digitally scanned to observe 
degradation. Surface area of each scaffold was calculated using an image analysis program 
(ImageJ, National Institutes of Health, Bethesda, MA). Area was normalized by its original value 
(day 0) to calculate percent change in area. After 28 days, samples were fixed in 10% formalin 
(Fisher Scientific, Fair Lawn, NJ). 
Microstructural changes were compared using scanning electron microscopy (SEM). 
Samples were dehydrated daily in an increasing ethanol series (70%, 80%, 90%, 100%) and 
stored in a desiccation chamber overnight. Samples were then critical-point dried using liquid 
carbon dioxide (Tousimis, Cleveland, OH). After applying a 50 mbar vacuum and inducing 
eccentric rotation, samples were sputter coated with gold-palladium (Au-Pd) for 45 seconds [4]. 
Samples were imaged using a Phillips XL30 (FEI Company, Hillsboro, OR) SEM. Beam voltage 
was 10 kV with a spot size of 5. Images were recorded at 500x magnification. 
2.2.4 Mechanical Testing 
Test specimens were prepared as right circular cylinders 25 mm in diameter and 30 mm 
in height for mechanical testing (Instron Model 5567, Grove City, PA) [5]. A compression test at 
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constant velocity (1 mm/min) was performed on hydrated samples (n = 5). Original dimensions 
were used to calculate stress and strain, and resulting curves were used to determine elastic 
modulus. Analysis was limited to the initial linear region of 10% strain [6]. 
Cylindrical samples of 1 cm diameter and 1 cm height were prepared in centrifuge tube 
caps for nanoindentation (n = 4). A TI950 Hysitron Tribometer (Minneapolis, MN), using a 90° 
conical PMMA tip, indented samples 10 µm in depth to determine relative sample stiffness 
(Figure 2.4). Stiffness was calculated as slope of tip removal curve between 40-90% 
displacement [7].  
2.2.5 Adipose-Derived Stem Cell Co-Culture and Osteogenic Differentiation 
Fibrin scaffolds were thawed and sectioned (1 mm thickness). Sections were sterilized 
using ethylene oxide gas (Anprolene, Andersen Products, Haw River, NC) exposure overnight 
before washing with phosphate buffered saline (PBS, Sigma D5773). Scaffolds were placed in 
tissue culture plates and cultured overnight under standard conditions before addition of passage 
2-3 ASCs (1x105 cells per cm2), which were previously isolated from a pig transgenic for green 
fluorescent protein (GFP) [8]. ASCs were cultured in DMEM with 10% FBS incubated with 5% 
carbon dioxide at 39°C. Cell attachment to fibrin was observed with a fluorescent microscope.  
At 80% confluence, media was supplemented with 10 mM β-glycerophosphate (Sigma 
G9891), 50 µM ascorbic acid (Sigma A4403) and 1 µM dexamethasone (Sigma D4902) to 
induce osteogenic differentiation [9]. Cells were cultured for 0, 14, and 28 days before fixation in 
10% formalin. Circular nodules form during osteogenic differentiation, which were imaged using 
a fluorescent microscope (Nikon Diaphot-TMD, Melville, NY) and digital camera (Nikon 
DXM1200). After fluorescent imaging, average area per nodule (n=30) was quantified using 
ImageJ (National Institutes of Health, Bethesda, MA). Average nodule radius was calculated 
assuming a circular nodule, using the equation [9]: 
Radius = sqrt(Area / π) 
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2.2.6 Statistical Analysis 
Quantitative data are presented as mean ± standard error. One-way analysis of 
variance (ANOVA) was performed using SAS 9.2 statistical analysis software (SAS Institute, 
Cary, NC). Fisher’s exact test was used for pairwise mean comparisons. A total of 3 scaffolds 
per treatment per timepoint were analyzed for a total of 18 scaffolds and 30 nodules per 
treatment per timepoint (n = 30). Significance was evaluated using an alpha level of 0.05.  
2.3 Results 
2.3.1 Coagulation Time 
 Average coagulation time of untreated whole blood was 121 seconds (Figure 2.1a). 
Treatment with calcium phosphate reduced coagulation time by 25% (p = 0.25) while treatment 
with red blood cell lysis buffer increased clotting time by 35% (p = 0.081, Figure 2.1b). 
Following normalization, differences between treatments were significant (calcium phosphate p 
= 0.022, RBC lysis p = 0.0071). Calcium chloride treatments could not be assessed due to low 
stiffness, as samples remained in motion during manual agitation even after completing 
coagulation. 
2.3.2 In Vitro Degradation 
Evidence of bulk degradation was present in most treatments (Figure 2.2). In addition, 
increasing fetal bovine serum concentration generally resulted in a higher amount which was 
degraded. Control blood clots had 98% remaining after 28 days in culture with serum-free 
DMEM (0% FBS) and 80% remaining after culture in DMEM with 10% FBS (Figure 2.3). Clots 
treated with calcium chloride were more resistant to degradation (92% remaining, p = 0.097) 
while clots treated with red blood cell lysis buffer were less resistant (74% remaining, p = 0.14).  
Analysis of scaffolds using scanning electron microscopy (SEM, Figure 2.4) displayed 
limited structural differences for whole blood, calcium chloride, and red blood cell lysis buffer 
scaffolds. Calcium phosphate treatment resulted in a more granular surface with notable 
roughness. Vacuum and compression-treated scaffolds appeared smoother. 
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2.3.3 Mechanical Testing 
Measured by compression testing, the average elastic modulus of fibin scaffolds (Figure 
2.5) derived from whole blood was 1.9 kPa. Scaffolds treated with RBC lysis buffer were higher 
in stiffness by 25% (p = 0.092). In addition, scaffolds treated with CaHPO4 had a similar higher 
stiffness (p = 0.089). Scaffolds coagulated under vaccum or mechanical compression showed no 
change in stiffness. Treatment with CaCl2 significantly reduced stiffness by 37% (p = 0.025, 
Figure 2.6).  
Nanoindentation (Figure 2.7) stiffness measurements were significantly higher for 
scaffolds treated with calcium phosphate (average 94 kPa, p = 0.00024) compared to whole 
blood (47 kPa). Scaffolds treated with red blood cell lysis buffer also were higher compared to 
whole blood (p = 0.095). Normalization by pig (Figure 2.8) resulted in stiffness nearly two times 
higher for calcium phosphate (p = 0.0053) and a trend higher for red blood cell lysis buffer (p = 
0.064). Scaffolds from other treatments could not be accurately measured due to low stiffness. 
2.3.4 Osteogenic Differentiation 
GFP-ASCs attached onto fibrin within 2 days and differentiated into an osteogenic 
phenotype when cultured in media supplemented with dexamethasone, β-glycerophosphate and 
ascorbic acid (Figure 2.9). Over time, bone-like nodules formed which were observed using 
fluorescent microscopy. Osteogenic nodules were observed by 7 days and increased in density 
until 14 days. Nodules increased in size through 21 days, then appeared to grow more slowly 
until 28 days. 
Average area per nodule (Figure 2.10) and average radius (Figure 2.11) generally were 
lower on fibrin derived from whole blood compared to control polystyrene (tissue culture plastic, 
p = 0.029). However, nodules on fibrin scaffolds treated with calcium phosphate (p = 0.042) 
were greater in size compared to control whole blood.  
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Figure 2.1: Coagulation time of blood in a centrifuge tube (a). Times normalized relative to 
untreated whole blood for each individual pig (b). Treatments with different superscripts 
significantly differ (p < 0.05). 
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Figure 2.2: Representative 2-D cross-sections of fibrin scaffolds after 28 days in culture. Presence of 
FBS increased degradation rate, which varied depending on scaffold treatment. 
 
 
 
Figure 2.3:  Relative change in cross-sectional area during culture in 10% fetal bovine serum. 
Scaffold treatment affected rate of degradation, but treatments remained stable over the timeframe 
of osteogenic differentiation. Treatments with different superscripts significantly differ (p < 0.05). 
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Figure 2.4: Representative scanning electron microscope (SEM) images in fibrin scaffolds. While 
whole blood, calcium chloride, and red blood cell lysis buffer scaffolds displayed limited differences 
in structure, calcium phosphate treatment resulted in a more granular surface with notable 
roughness. Vacuum and compression-treated scaffolds appeared smoother. 
32 
 
 
Figure 2.5: Experimental set ups for compression testing (left) included preparing right circular 
cylinders 25 mm in diameter and 30 mm in height and compressing samples using an Instron 
Model 5567. Calculated stresses and strains were used to determine elastic modulus. 
Nanoindentation (right) used samples 1 cm in diameter and 1 cm in height. Samples were indented 
using a 90° conical PMMA tip, indenting 10 µm in depth. Stiffness was calculated as slope of tip 
removal curve between 40-90% displacement. 
 
 
 
Figure 2.6: Compression testing results displayed higher stiffness in scaffolds treated with RBC 
lysis buffer and calcium hydrogen phosphate. Scaffolds coagulated under vacuum or mechanical 
compression showed little difference and scaffolds treated with calcium chloride were lower in 
stiffness. Treatments with different superscripts significantly differ (p < 0.05). 
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Figure 2.7: Compared to whole blood, nanoindentation results were significantly higher in stiffness 
for scaffolds treated with calcium phosphate. Scaffolds treated with red blood cell lysis buffer 
trended higher compared to whole blood but not significantly. Treatments with different 
superscripts significantly differ (p < 0.05). 
 
Figure 2.8: Stiffness normalized by individual pig were significantly higher in stiffness for scaffolds 
treated with calcium phosphate. Scaffolds treated with red blood cell lysis buffer trended higher 
compared to whole blood but not significantly. Treatments with different superscripts significantly 
differ (p < 0.05).  
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Figure 2.9: Paired phase contrast and flourescent images of ASCs (white arrows)  expressing green 
fluorescent protein attaching to (a,b and c,d) and differentiating (e,f) on fibrin scaffolds. Scale a and 
b – 25 µm. Scale c and d – 50 µm. Scale e and f – 100 µm.   
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Figure 2.10: Average nodule area during osteogenic differentiation on scaffolds of various 
treatments. Treatments with different superscripts significantly differ (p < 0.05).  
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Figure 2.11: Average nodule radius during osteogenic differentiation on scaffolds of various 
treatments. Treatments with different superscripts significantly differ (p < 0.05).   
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2.4 Discussion 
 The primary objective of these experiments was to develop an optimal preparation of 
whole blood-derived fibrin which was practical, biocompatible, and osteoconductive. Based on 
the results, fibrin supplemented with granules of calcium hydrogen phosphate (CaHPO4) was 
determined to be the most suitable formulation of those examined and was appropriated for use 
in the in vivo experiment (Chapter 4). Using calcium phosphate resulted in a fibrin scaffold 
which coagulated faster (p = 0.022), had a rougher surface, and higher stiffness, which are 
desirable properties for practical usage during surgical operations and for scaffolds used in bone 
tissue engineering. 
Calcium phosphates and calcium chlorides act as natural pro-coagulants due to increased 
concentrations of soluble calcium ions, an essential element for activation of both factor X and 
thrombin in the coagulation cascade [10]. However, these ionic compounds are on separate 
extremes of the solubility scale, with CaCl2 being almost completely soluble in water while 
CaHPO4 has limited solubility, though comparatively high among calcium phosphates. 
Differences in solubility affect bioavailability of calcium ions and thus modify their effect during 
fibrin polymerization. From calcium chloride, the increased soluble calcium ion concentration 
likely allows for more simultaneous initiation sites of fibrin polymerization [11], resulting in a 
scaffold that gels more rapidly with lower average chain length and reduced stiffness.  
For calcium phosphate, this effect is mitigated by fewer available calcium ions, while 
providing relatively insoluble nucleation sites for the initiation and stabilization of fibrin 
polymerization. Initial contact activation is the longest phase of the coagulation process [2]. 
Addition of calcium phosphate granules significantly increases available surface area for contact 
activation and is likely to account for the observed reduction in coagulation time with calcium 
phosphate. In addition, concentration of fibrinogen also has an important effect on coagulation 
with lower concentrations resulting in fibrin gels which polymerize slower. Dilution of 
fibrinogen and other coagulation factors by red blood cell lysis buffer is likely to explain its 
slower coagulation time. 
For both in vitro and in vivo environments, fibrinolysis proceeds through two related 
mechanisms, bulk and enzymatic degradation [12]. Bulk degradation is the result of water 
infiltration and hydrolysis, reducing chain lengths and network connectivity [13]. Enzymatic 
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degradation proceeds primarily through the enzyme plasmin, which circulates in an inactive form 
in the blood [12] and is present in fetal bovine serum. Addition of FBS to culture media 
increased fibrinolysis regardless of treatment, indicating the significant role of enzymatic 
degradation, while bulk degradation was slower in comparison.  
Fibrin scaffolds treated with calcium chloride or coagulated under vacuum displayed 
notable reductions in degradation (higher area remaining) compared to fibrin scaffolds derived 
from whole blood. Though multiple mechanisms may determine this result, the chemical 
property of shorter average chain length during is likely to be a dominant factor for calcium 
chloride treatment [14]. However, for vacuum coagulation, the physical property of reduced 
porosity aids in reducing water infiltration and surface exposure to plasmin, slowing both bulk 
and enzymatic degradation [15]. In contrast, scaffolds treated with red blood cell lysis buffer 
likely had increased water infiltration and plasmin exposure, due to the osmotic dissolution of 
red blood cells, resulting in was higher (p = 0.097) degradation (lower area remaining) compared 
to controls. 
For attachment-dependent cell types such as adipose-derived stem cells, a rough surface 
is generally more preferable than a smooth surface [16]. Surface roughness provides more 
opportunities for multidirectional cell attachments more similar to that experienced by cells in 
vivo, as well as increased surface area for attachment and material transport. For fibrin scaffolds, 
roughness is primarily due to red blood cells (7 µm average diameter). Red blood cells likely 
account for the surface roughness viewable by scanning electron microscopy for whole blood 
and calcium chloride treatments, while osmotic destruction of red blood cells by red blood cell 
lysis buffer may explain the slight increase in surface roughness. However, ASCs generally 
cannot directly attach to red blood cells. In contrast, attachment-dependent cell types are capable 
of attachment to calcium phosphate granules [17], which have granule sizes on a similar scale. 
Addition of granules appears to provide increased surface roughness to fibrin scaffolds. Use of 
vacuum or mechanical compression appears to flatten red blood cells, causing fibrin to appear 
smoother.  
In addition, adipose-derived stem cells, among other fibroblast-like cell types, are not 
known to maintain receptors for direct attachment to fibrin. Therefore, cell attachment is likely to 
proceed through intermediates such as fibronectin [18], which circulates in blood along with 
39 
 
fibrinogen and becomes entrapped within the developing blood clot during coagulation [19]. 
Reduced direct attachment to fibrin may help explain in part the limited success in the use of 
fibrin-only glues for tissue regeneration. ASCs appeared to viably attach and differentiate on 
whole blood derived fibrin scaffolds.  
Fibrin scaffolds derived from whole blood maintain several advantages over those 
prepared from only fibrinogen and thrombin. These include simple and inexpensive collection in 
addition to retaining essential blood constituents in the wound healing process such as 
fibronectin and platelet aggregates [20]. However, the use of whole blood-derived fibrin comes 
at the cost of reduced operative control of fibrin polymerization as well as reduced stiffness of 
the clot due to the presence of red blood cells.  
 Bulk stiffness of fibrin scaffolds, as measured by compression testing, did not 
appreciably increase from a practical standpoint regardless of treatment, and remains several 
orders of magnitude lower than trabecular bone [21]. However, microscale stiffness, as measured 
by nanoindentation, significantly increased with calcium phosphate treatment compared to 
controls. The effect of calcium phosphate may be related to its inherently high stiffness as a 
ceramic as well as the potential of it granules to act as anchors for the fibrin network. The 
mechanical properties of fibrin-calcium phosphate composites can be approximated as a 
weighted average of the two substances [22]. Increased stiffness at the microscale has been 
demonstrated to favor osteogenic differentiation of adipose-derived stem cells, whereas softer 
surfaces favor other cell types, such as neurons and myocytes [23]. The mechanisms for this 
phenomenon are under investigation, but are related to the interdependent relationship between 
mechanical forces on the extracellular matrix and gene expression.  
 A difference in measured stiffness values of approximately one order of magnitude was 
observed between the methods of compression testing and nanoindentation. These results are 
likely explained by the hydrated, physiological testing conditions and the role of water in fibrin 
viscoelasticity [24]. Surface tension is a much more dominant force in nanoindentation 
measurements. Water is allowed to flow more freely under a bulk compression testing regimen, 
which may reduce observed elastic (storage) modulus. Application of a sinusoidal stress, used in 
methods such as dynamic mechanical analysis [25], could potentially rectify this difference in 
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observed values and better account for the viscoelastic behavior of fibrin scaffolds, which are 
similar to hydrogel polymers. 
In terms of osteoconductivity, one notable result is the tendency of ASCs to form larger 
nodules on tissue culture plastic (irradiated polystyrene) compared to whole blood-derived fibrin. 
This result is likely explained in part by methods used in ASC isolation [9], which includes 
expansion of cells which adhere onto tissue culture plastic. While starting as a heterogeneous cell 
population, the cells which attach and divide most rapidly dominate in number [26]. Therefore, 
ASC isolation methods introduce a strong selection for attachment to polystyrene. 
The ability of ASCs to attach and migrate towards each other is essential for the 
formation of osteogenic nodules over a timescale of weeks. The potential factors of improved 
cell attachment, presence of calcium and phosphate ions, surface roughness, and increased 
stiffness on the microscale may each play a role in the increase in osteoconductivity of ASCs for 
fibrin treatments of red blood cell lysis buffer, calcium chloride and calcium phosphate, as 
measured by histomorphometry. Treatment of fibrin scaffolds with calcium phosphate appears to 
improve each of these factors, resulting in the decision to utilize calcium phosphate as a 
supplement to fibrin for the in vivo experiment. 
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CHAPTER 3                                                                                                                                 
IN VITRO MIGRATION IN PLATELET-RICH PLASMA  
3.1 Overview 
 This chapter details the protocol for collecting platelet-rich plasma (PRP), its 
characterization, and its effects on the proliferation and migration of porcine adipose-derived 
stem cells (ASCs). The primary aim of these studies was to analyze in vitro ASC migration in 
varying concentrations of growth factors derived from the platelet-rich fraction of centrifuged 
plasma. ASCs were hypothesized to migrate at a faster average velocity with increasing PRP 
concentration. Whole blood was collected with sodium citrate anticoagulant and underwent two 
centrifugations. The first slower spin (905 xg) was to remove red blood cells to collect plasma 
and the second faster spin (2510 xg) was to collect the fraction with a high platelet concentration. 
Platelet concentration increased 3.5-fold compared to plasma, within the prescribed therapeutic 
range. For long-term culture of ASCs, dilution with DMEM to concentrations less than 30% was 
found to be necessary for cell viability. ASC rate of proliferation was comparable to that in fetal 
bovine serum (FBS), a standard cell culture media supplement. In addition, velocity of ASC 
migration increased in cultures supplemented with 20% or 30% PRP. Generally, PRP was 
determined to be a media supplement with similar effects as FBS, potentially making it a suitable 
substitute for in vitro expansion of ASC populations. It is likely these results are explained in 
part by similarities in growth factor concentrations and their effects. Based on these results, 20% 
PRP was selected as the concentration for the in vivo study (Chapter 4). 
3.2 Methods 
3.2.1 Blood Collection and Processing 
PRP was collected in sterile 1-liter containers from 4 pigs using sodium citrate (3.3%, 
Sigma W302600, St. Louis, MO) as the anticoagulant at a ratio of 8 mL blood to 1 mL 
anticoagulant. An initial centrifugation spin was performed at 1800 rpm (905 xg) for 15 minutes 
for removal of RBCs and collection of plasma. A subsequent spin of collected plasma at 3000 
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rpm (2510 xg) for 10 minutes separated platelets [1]. The lower half was considered PRP while 
the upper fraction was considered platelet-poor plasma (P3). Samples were stored at -20°C.   
3.2.2 Platelet Concentrations 
 Plasma, PRP and P3 were assessed for platelet concentration using a hemocytometer and 
phase contrast microscope (Nikon Diaphot-TMD, Melville, NY). Platelets were counted at 400x 
magnification in triplicate. 
3.2.3 Adipose-Derived Stem Cell Proliferation 
 Serum was thawed to room temperature, and then heated to 56°C for 30 minutes to 
inactivate complement. Platelets were degranulated using 2.4 mM calcium chloride (Sigma 
C7902) before filtration (0.2 µm syringe filters, Nalgene, Rochester, NY). ASCs were thawed 
and cultured in DMEM (Sigma D5648) supplemented with FBS (BenchMark, Gemini Bio-
Products, Sacramento, CA), PRP, or P3  at concentrations of 10% or 20%. At passage 3-4, cells 
were seeded at 1.0 x 104 cells/mL in 6-well plates. Cells were trypsinized and counted in 
duplicate on a hemocytometer after 0, 1, 2, 4, 6 and 10 days. Average doubling time (Td) was 
calculated using the equation [2,3]: 
Td = (t2 – t1) * log (2) / log (q2/q1) 
using counts (q1,2) from day 2 (t1) and day 6 (t2) time points during the logarithmic growth phase. 
3.2.4 Transwell Migration Assay 
 A polyethylene terephthalate (PET) 8-µm pore insert for 6-well plates (BD Biosciences, 
San Jose, CA) was used to assess ASC migration. ASCs were starved in serum-free DMEM 
overnight before seeding (1 x 105 cells/mL) onto the top migration well [4]. The lower chamber 
contained DMEM (control), FBS, PRP, or P3 (10, 20%). After incubation at 39°C in 5% CO2 for 
3, 8 and 24 hours, ASCs on the bottom well were counted, performed at 100x magnification in 
duplicate. 
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3.2.5 PDMS Stamp Production 
Poly-dimethylsiloxane (PDMS, Dow Corning, Midland, MI) stamps were produced using 
standard soft lithographic methods, which consist of a silicon master pattern to produce PDMS 
molds [5]. In a clean room (Beckman Institute), the master was formed using a photomask 
printed with the 2 mm circular patterns which selectively blocked the passage of UV light onto 
an epoxy photoresist (SU-8, MicroChem, St. Newton, MA). Photoresist was coated onto silicon 
wafers at 5 µm thickness using a 1000 rpm spin speed and 1 minute pre-bake at 65°C. Sections 
of photoresist exposed to UV light polymerized and attached to the silicon wafer while 
unexposed portions were subsequently washed away using 70% ethanol, resulting in a negative 
of the original photomask. Wafers with 2 mm photoresist patterns were baked at 95°C for 1 
minute to complete polymerization.  
After liquid monomer was mixed in a 10:1 mass ratio with catalyst (Sylgard, Dow 
Corning), PDMS was poured onto the master. Following removal of bubbles by vacuum, PDMS 
was allowed to set under 50 kg of weight overnight. Heating at 60°C for 2 hours completed 
polymerization. PDMS formed a mold which matched the pattern of the original photomask.  
3.2.6 Stamp Migration Assay 
PDMS stamps were sterilized with 70% ethanol and allowed to air dry before placing in 
12-well plates. Serum-starved ASCs (1.0 x 107 cells/mL) were loaded in each well and cultured 
in serum-free DMEM for 4 hours to allow cell attachment. Treatments included medium 
consisting of DMEM with varying PRP (0, 10, 20, 50, 80, 90, 100%) or FBS (10, 20%) 
concentrations. Plates were placed into a specialized incubator equipped with a phase contrast 
microscope (Olympus WeatherStation, Precision Control, Tacoma, WA) and a camera capable of 
time-lapse imaging to track cell migration. Images were captured every 15 minutes for 48 hours. 
Displacement and distance traveled of randomly selected ASCs over time (n = 30) were 
measured using ImageJ [6]. Average displacement was used to calculate the average ASC 
velocity. 
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3.2.7 Statistical Analysis 
Quantitative data are presented as mean ± standard error. One-way analysis of 
variance (ANOVA) was performed using SAS statistical analysis software (SAS Institute, Cary, 
NC). Fisher’s exact test was used for pairwise mean comparisons. A total of 30 cells per 
treatment (n = 30) were analyzed. Significance was evaluated using an alpha value of 0.05. 
3.3 Results 
3.3.1 Platelet Concentration 
For every 5 mL of whole blood, 1 mL of platelet rich plasma was acquired (Figure 3.1). 
Through centrifugation, platelet concentration of PRP was significantly higher (p < 0.001) by a 
factor of 3.5 over plasma from the same animal (Figure 3.2). 
3.3.2 Adipose-Derived Stem Cell Proliferation 
Addition of serum or plasma to DMEM resulted in a trend of shorter average doubling 
time of ASCs (Figure 3.3). While limited for platelet-poor plasma (P3, p = 0.17), the effect was 
more pronounced for media supplemented with PRP (p = 0.073) or FBS (p = 0.091). Increasing 
PRP concentration appeared to have a limited effect on doubling time (p = 0.069, Figure 3.4). 
3.3.3 Transwell Migration Assay 
 After 24 hours, ASC migration towards 20% PRP was 2.8 times higher than DMEM 
controls (p = 0.023). This effect was similarly observed in 20% FBS (p = 0.031), while migration 
was more limited towards 20% P3 (p = 0.035). 
3.3.4 Stamp Migration Assay 
 After tracking for 48 hours (Figure 3.6), average cell velocity (Figure 3.7) was higher in 
media supplemented with FBS (p= 0.0014) or PRP (p = 0.0013). Velocity was significantly 
higher at 20% PRP compared to 10% PRP (p = 0.0003) with no significant difference between 
30% PRP and 20% PRP (p = 0.42). ASCs were not viable long-term at concentrations above 
30% PRP. 
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Figure 3.1: Platelet-rich plasma centrifugation process, (a) whole blood with 3.3% sodium citrate 
anticoagulant. (b) Separation into plasma (black arrow), buffy coat (grey arrow) and red blood cell 
(white arrow) fractions after first centrifugation. (c) Platelet-rich plasma consisting of upper 
portion of buffy coat and lower fraction of plasma after second centrifugation.  
 
 
 
 
Figure 3.2: Platelet concentration increased 3.5 fold in platelet-rich plasma over whole plasma 
while platelet concentration decreased in platelet-poor plasma. Treatments with different 
superscripts significantly differ (p < 0.05). 
b 
c 
a b c 
a 
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Figure 3.3: Representative pictures of ASC proliferation in DMEM, 10% FBS, and 10% PRP after 
2, 4 and 6 days. Scale bar is 100 µm. 
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Figure 3.4: Average doubling time of ASCs trended towards decrease (0.1 > p > 0.05) in platelet-
rich plasma and fetal bovine serum compared to control DMEM and platelet poor plasma though 
no results were significantly different. Treatments with different superscripts trended toward 
difference but were not significantly different (0.01 > p > 0.05).  
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Figure 3.5: Migration across polyethylteraphthalate wells significantly increased using platelet-rich 
plasma and fetal bovine serum. Treatments with different superscripts significantly differ (p < 
0.05).  
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Figure 3.6: Representative images of cell migration in DMEM control and 20% PRP after 0, 24, 
and 48 hours. Scale bar is 200 µm.  
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Figure 3.7 Average cell velocity significantly increased in fetal bovine serum and platelet-rich 
plasma compared to control DMEM. Effect of PRP dose was significant up to 20% PRP. ASCs 
were not viable at PRP concentrations above 30%. Treatments with different superscripts 
significantly differ (p < 0.05).  
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3.4 Discussion 
The goal of these experiments was to determine an optimal concentration of platelet-rich 
plasma which increased adipose-derived stem cell proliferation and migration while maintaining 
long-term cell viability. Based on the results, a mixture of 20% platelet-rich plasma and 80% 
Dulbecco’s modified Eagle medium was determined to be the optimum mixture and was adopted 
for use in the in vivo experiment (Chapter 4). Using PRP at this concentration resulted in ASCs 
which traversed through narrow channels in greater number, trended towards proliferating at a 
faster rate, and migrated at a faster velocity while maintaining viability in culture long-term. 
Faster proliferation and migration ultimately results in greater effective numbers of ASCs at the 
site of the defect and helps to relieve the requirement of isolating and collecting high numbers of 
these adult stem cells during surgery.  
Injection of PRP along with adult stem cells at the site of the wound may be preferable to 
expansion in cell culture, which carries risks of contamination, oncogenic mutation, as well as 
significant regulatory and clinical infrastructure burdens [7]. However, as cell-based therapies 
continue to be developed, optimal growth mediums which are safe and effective will be 
important. Currently, fetal bovine serum and custom serum-free formulations are widely 
employed, with FBS carrying advantages of effectiveness and cost but disadvantages of potential 
disease transference and immune reactions, such as spongiform encephalopathy or serum 
sickness, respectively [8,9]. Platelet-rich plasma poses an alternative for in vitro ASC expansion 
[10]. According to the results, effectiveness in promoting proliferation and migration were 
roughly equivalent to FBS. In addition, PRP could be individualized for each patient by blood 
draws and processing before a grafting procedure. While the chance for contamination remains, 
risks of disease transference are generally eliminated, making PRP an attractive potential 
substitute for FBS or serum-free for growth factor mediums. 
Protocols for concentrating platelets vary by amount of blood collected, centrifugation 
speed and time, as well as fractions considered to be platelet-rich plasma [11]. The two-step 
approach used in this study, which has been used clinically, resulted in a 3.5-fold increase (p < 
0.001) in platelet concentration compared to plasma. Ranges of platelet concentration 
approximately 3 to 6-fold are thought to be therapeutic and generally recommended for clinical 
use of platelet-rich plasma [12]. Concentrations above this level may result in unacceptably 
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severe symptoms of inflammation, such as pain and swelling, or potential paradoxical effects in 
wound healing. Translating this platelet concentration into growth factor yield, an estimated 0.06 
ng of PDGF is produced per one million platelets, or about 1,200 molecules of PDGF per platelet 
[13,14]. Therefore, while PRP is a potent autologous therapy, dosing remains an important but 
less-studied factor in therapeutic regimens, in order to optimize both growth factors as well as 
inflammatory factors which are simultaneously released during platelet degranulation. 
 Another important result of this study is the low viability of ASCs at concentrations 
above 30% PRP, which is important because PRP appeared to form a stable gel at concentrations 
above 50% and remained in solution at lower concentrations. While initially thought to be 
toxicity from residual sodium citrate anticoagulant or calcium chloride for platelet degranulation 
in the culture media, the observed low viability at high concentrations may be more likely due to 
osmotic imbalance because of the high protein concentrations as well as lower concentrations of 
DMEM, which has essential elements for cell growth such as amino acids, salts, vitamins and 
glucose. Studies which utilize PRP at high concentration along with cellular therapy may have 
reduced performance due to cell losses. Standard concentrations of FBS used with DMEM are 
generally 10% to 20% depending on application [15]. Culturing ASCs with PRP at higher 
concentrations may require modification of standard DMEM to preserve ASC viability. 
The effect of platelets on ASC proliferation is the result of two primary growth factors, 
PDGF and TGF-β [16]. Average doubling time decreased (faster proliferation) for PRP and FBS 
treatments while doubling time was longer in platelet-poor plasma and control DMEM. For this 
study, doubling time was independent of concentration for PRP. This result may be due to limits 
in the rate of mitosis set by steps such as DNA synthesis and cell division [17], which might not 
be further stimulated by growth factor administration.   
For the transwell migration assay, the ability of ASCs to traverse channels on the order of 
the size of the nucleus towards a growth factor gradient is simulated. During a bone injury, tissue 
becomes necrotic and marked for debridement by macrophages and osteoclasts resulting in the 
rapid formation of channels for migration throughout the damaged bone. A baseline level of 
ASCs were found to migrate with no growth factor gradient present (DMEM controls) and is 
likely due following other gradients, such as glucose , oxygen and pH, found in the fresh media 
of the lower chamber [18]. Addition of PRP, FBS, or platelet-poor plasma all appeared to 
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enhance the process of migration. Growth factor gradients stimulate migration by differential 
membrane receptor stimulation on the forward migrating end with higher concentration 
compared to the end with lower concentration and are important for increasing the number of 
MSCs to the site of the defect. 
In the stamp migration assay, ASCs did not migrate towards any gradient, but instead 
generally moved towards newly opened space in the cell culture plate, at a greater velocity in 
PRP (p = 0.0014) or FBS (p = 0.0013) compared to control DMEM. The stamp migration assay 
represents a rough two-dimensional approximation of a bone defect in that live cell density 
decreases as capillary networks are damaged. Cell-cell signaling results in proliferation and 
migration at low local confluencies and is reduced as confluency increases, known as contact 
inhibition, a property of normal, non-cancerous cells [19]. In addition to the removal of contact 
inhibition, average cell velocity appeared to be concentration-dependent up to 20% PRP (p = 
0.0003) before becoming independent and less viable at 30% PRP (p = 0.42). These results may 
suggest a therapeutic limit for the dosage of PRP which would be effective for the promotion of 
proliferation and migration of ASCs, as membrane receptors may become saturated and gene 
expression maximally upregulated. 
 Because the growth factors released from platelets primarily affect cell proliferation and 
migration, a possible improvement to better simulate the bone regeneration process could be 
bone morphogenetic protein (BMP-2 or BMP-7) or differentiation media (dexamethasone, 
ascorbic acid, β-glycerophosphate) supplementation. Regeneration is initiated by platelets, 
primarily through the release of PDGF, FGF, and TGF-β, which act to induce mitosis and 
migration of scarce (1 in 250,000 cells for an adult [20]) mesenchymal stem cells, greatly 
increasing their number during an injury. While TGF-β plays an important role in collagen 
production and organization, it is the BMPs, not found in PRP, which direct the maturation of 
osteoblasts as well as the eventual remodeling of the tissue. Supplementing with these factors 
may provide a better understanding of the entire bone regeneration process. In summary, 
platelet-rich plasma at the appropriate concentration increases proliferation, migration, and 
velocity of cell spreading and presents an alternative culture media supplement. 
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CHAPTER 4                                                                                                                                 
IN VIVO AUTOLOGOUS BONE TISSUE ENGINEERING 
4.1 Overview 
 This chapter covers the process of obtaining adipose-derived stem cells from liposuction, 
platelet-rich plasma and fibrin scaffolds from blood draws, creation of critical-size bone defects, 
and analysis of bone healing after 8 weeks. The primary aim was to assess therapeutic effects of 
autologous PRP and fibrin scaffolds combined with autologous ASCs for critical-size defects in 
the pig mandible. Fibrin scaffolds of the appropriate composition (calcium hydrogen phosphate 
composite, Chapter 2) and platelet-derived growth factors of the appropriate concentration (20%, 
Chapter 3) were hypothesized to accelerate healing in porcine mandible bone compared to ASC-
only injections and untreated controls. Three treatments included the use of autologous ASCs 
from liposuction with the addition of platelet-rich plasma, fibrin scaffolds, or as cell-only 
controls. All three treatments using ASCs were determined to increase bone mineral density and 
bone volume fraction compared to untreated controls. In general, addition of both platelet rich 
plasma and fibrin scaffolds to autologous ASCs from liposuction improved bone healing of 
critical-size defects. Based on these results, adipose-derived stem cell therapies for bone healing 
are recommended to add together with either platelet-rich plasma or use a calcium phosphate-
fibrin composite to encapsulate the cells for further improvement in healing of critical-sized 
defects.  
4.2 Methods 
4.2.1 Liposuction 
The University of Illinois Institutional Animal Care and Use Committee approved all 
following procedures. Twelve female Yorkshire pigs (Sus scrofa domesticus) aged 1-3 years and 
weighing 170-275 kg were included in the study. For ASC extraction, liposuction was performed 
using standard protocols (Protocol A.1) [1]. Following general anesthesia (5% Isoflurane, 
Baxter, Deerfield, IL) and sufficient skin sterilization with Betadine (Butler Animal Health, 
Dublin, OH), 70% ethanol, and zephiran chloride (Winthrop Laboratories, New York, NY), 
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pinpoint incisions were made at 4-6 locations on either side of the dorsal midline using a trocar. 
Sterile 0.9% saline (Vedco, St. Joseph, MO) with epinephrine (1 mg/L, IMS Limited, El Monte, 
CA) was injected into subcutaneous adipose deposition sites using a 60 mL syringe connected to 
a Cobra cannula (3 mm diameter, 25 cm length, Shippert Medical, Centennial, CO). 
Approximately 10-20 mL of saline was infused per injection and allowed to remain several 
minutes before collection to promote vasoconstriction and reduce blood loss. A liposuction 
cannula (Triport, 4 mm diameter, 15 cm length, Shippert Medical) connected to a suction pump 
(75 kPa, Schuco Inc., Indianapolis, IN) was inserted to collect the lipoaspirate (300-400 mL 
total). Liposuction time was 60-75 minutes. 
4.2.2 Isolation of Adipose-Derived Stem Cells 
Collected lipoaspirate was added to 250 mL centrifuge tubes (Corning Inc., Corning, NY) 
and mixed on a shaker plate with an equal volume of type I collagenase (0.075%, Sigma C2674) 
for 60 minutes at 37°C to digest extracellular matrix [2]. The mixture was centrifuged for 10 
minutes at 1400 rpm (547 xg) to separate low-density adipocytes from the higher-density stromal 
vascular cell fraction, which contains ASCs along with other additional cell types, such as 
fibroblasts, endothelial cells and smooth muscle cells. The remaining cell pellet was removed 
and placed in 50 mL conical tubes to be centrifuged for 5 minutes at 1400 rpm (547 xg). Two 
mL of red blood cell lysis buffer (Sigma R7757, St. Louis, MO) was added to the pellet for 2 
minutes, then diluted with PBS (Sigma D5773) and centrifuged (repeated 1-2 times for removal 
of red blood cells). The final pellet was mixed with serum-free DMEM (Sigma D5648) and 
filtered with a 100 µm cell strainer (Fisher Scientific, Fair Lawn, NJ). Cells collected were split 
into two syringes, each having a volume of 5 mL. Processing times for isolation of ASCs was 
120-150 minutes. Following 10% formalin (Fisher Scientific) fixation after 5 and 60 minutes, the 
number of nucleated cells was estimated using DAPI (Sigma D9542) staining and 
hemocytometer counting. A tracer amount (1 million) of GFP-ASCs was added to the cell 
injections of 3 pigs to analyze cell engraftment.  
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4.2.3 Surgical Procedures 
Following completion of liposuction, pigs were placed in a supine position with sufficient 
padding. Lower jaws were shaved and sterilized before placing iodine (Ioban, 3M, St. Paul, MN) 
and thyroid drapes (Kimberly Clark, Roswell, GA). Initial approach through skin was made by 
scalpel and followed up by electrocautery pencil (ConMed, Utica, NY) through fat and muscle. 
Periosteum was moved by periosteal elevator. Transcortical osteotomies, 25 mm in diameter, 
were performed on the posterior region of the mandible (ramus) using a trephine (Irwin Tools, 
Huntersville, NC) and power drill (Milwaukee Tools, Brookfield, WI) with adequate irrigation 
[3,4]. One surgical defect was created on each side of the ramus of the mandible (two total per 
pig). Removed bone cylinders were stored at -20ºC for later analysis. 
 Following removal of bone, the periosteum was sutured to form a pouch with 2-0 or 3-0 
polyglactin resorbable suture (Vicryl, Ethicon, Somerville, NJ). Treatments (5 mL volume) were 
injected into the defect and the periosteum was closed. Muscle, fat, and skin layers were then 
sutured continuously and the wound was sealed with cyanoacrylate skin glue (Vetbond, 3M, St. 
Paul, MN). Pigs were administered an analgesic (Banamine, Purdue Products, Somerville, CT) 
and antibiotic (Excede, Pfizer, New York, NY) and allowed to recover. Pigs were maintained on 
a soft diet for 1-3 days post-surgery and then resumed standard feed. 
4.2.4 Blood Extraction and Processing 
Blood draws were used to acquire the fibrin scaffolds and PRP. For PRP, blood was 
collected from the ear vein using a 21 gauge butterfly needle (Jorgenson, Loveland, CO) and a 
10 mL syringe filled with 1.5 mL of 3.3% sodium citrate. Blood was drawn to fill syringe up to 
10 mL total (8.5 mL blood). Anticoagulated blood was transferred to 15 mL centrifuge tubes. An 
initial centrifugation was performed at 1800 rpm (905 xg) for 15 minutes for removal of RBCs 
and collection of plasma. A subsequent spin of collected plasma at 3000 rpm (2510 xg) for 10 
minutes separated platelets [5]. A total volume of 2-3 mL of PRP was collected for injection (1-
1.5 mL per defect). Before injection, PRP was combined with cell/DMEM mixture (20% PRP 
concentration) and 50 µL of 10% calcium chloride for platelet activation. Cell-PRP mixture was 
then injected and the periosteum closed. 
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For fibrin scaffolds using whole blood, pigs were placed in a laterally recumbent position 
for each defect. Blood was collected from the ear vein in a 10 mL syringe already filled with 1 
mL of cell/DMEM mixture. Blood was drawn to fill syringe up to 4-5 mL total (3-4 mL blood), 
and then quickly injected into the defect while still in the liquid phase. Calcium hydrogen 
phosphate (0.1 mL of 0.3 M) was added and stirred in the defect. Following coagulation, 
periosteum was then sutured. 
4.2.5 Computed Tomography  
 Eight weeks post-surgery, mandibles were collected for analysis of bone healing. Four 
freshly harvested whole mandibles were scanned using computed tomography (GE Medical 
Systems, Waukesha, WI) at the University of Illinois Veterinary Medicine Teaching Hospital. 
Scanning parameters were 120 kV and 64 mA. Three-dimensional images were analyzed for 
gross anatomical information (Carestream, Rochester, NY). 
4.2.6 Dual Energy X-ray Absorptiometry 
Following removal of soft tissue, samples were scanned using DXA (Hologic QDR 
4500A, Bedford, MA) to measure bone mineral density (BMD). Two X-ray beams with different 
energy levels are passed through the bone and intensities are measured for each beam. Intensity 
varies depending on the thickness of the bone and amount of calcification. Based on the 
difference between the two beams, BMD was estimated. The original bone removed during the 
surgery served as a control for comparison and was scanned alongside the defect. Relative 
change in BMD was calculated as BMD of the defect divided by BMD of the original bone 
removed during surgery.  
4.2.7 Micro-Computed Tomography 
Samples were trimmed with a band saw and were scanned using microCT (Skyscan 1172, 
Kontich, Belgium) to determine the degree and location of bone defect healing [6]. MicroCT 
utilizes the variable X-ray attenuations of different materials to image samples. X-rays pass 
through the sample form a 2-D projection image. The sample was then slowly rotated, allowing 
the capture and output of a series of images. The scanner was operated at 75 kV and 100 mA 
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with a 1mm aluminum filter to reduce low energy noise. The medium resolution setting at 95% 
camera gain was utilized so that projection images were taken at 0.4 degree increments over a 
range of 180 degrees. A frame average of five projection images eliminated artifacts due to noise 
from the detector. To help eliminate ring artifacts caused by the detector elements, a random 
vertical movement of 5 was included. The projection radiographs were 16 bit TIFF files with 
1048 x 2000 pixels. 
A reconstruction algorithm (NRecon 1.1.4, Micro Photonics, Allentown, PA) digitally 
stacked and aligned these 2-D slices, resulting in a 3-D model of the sample which was used to 
analyze the two and three-dimensional morphological parameters of the defect. Quantitative 
analysis was based on the different attenuations of bone and soft tissue due to their different 
densities and compositions. Each volume element, or voxel (25 µm resolution), was assigned a 
gray scale value which was threshholded (Amira 5.0, Visualization Sciences, Burlington, MA). 
Bone volume fraction was calculated as bone pixels divided by total defect pixels. 
4.2.8 Histology 
Freshly isolated samples were exposed under a UV fluorescent flashlight and 
photographed to analyze cell engraftment (Figure 4.7). Following imaging, samples were fixed 
in 10% neutral buffered formalin (Fisher Scientific, Fair Lawn, NJ) for two weeks, dehydrated in 
an ethanol series (70, 80, 90, 100%) and infiltrated with methylmethacrylate (MMA, Acros 
Organics, Geel, Belgium) liquid monomer. Poly-methylmethacrylate (PMMA, Polysciences, 
Warrington, PA) solid beads and benzoyl peroxide (Sigma 33581) were added to induce 
polymerization and embed the samples. Samples were then sectioned perpendicular to the long 
axis of the cylindrical defect using a Buehler Isomet 100 diamond saw (Lake Bluff, IL) to yield 
500 µm thick sections. Sections were polished to 300 μm thickness with increasing grades of 
zirconium sandpaper. Three sections, one in the center and two at opposing edges, were used in 
the analysis.  
Sections were stained with Sanderson’s Rapid Bone Stain (Dorn & Hart Microedge, Villa 
Park, IL) and counterstained with acid fuchsin (Sigma F8129) to differentiate calcification (red) 
from soft callus (blue) and scar tissue (unstained). A digital scanner (HP Deskjet F4400, Miami, 
FL) captured images at full scale for quantification using image analysis software (ImageJ, 
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National Institutes of Health, Bethesda, MA). Mineralized bone area was calculated as area of 
tissue staining positively for bone (purple) per total defect area.  
4.2.9 Statistical Analysis 
Quantitative data are presented as mean ± standard error. One-way analysis of 
variance (ANOVA) was performed using SAS 9.2 statistical analysis software (SAS Institute, 
Cary, NC). Fisher’s exact test was used for pairwise mean comparisons. A total of 6 defects per 
treatment (n = 6) were analyzed for a total of 24 defects. Statistical significance was evaluated 
using an alpha value of 0.05. 
4.3 Results 
4.3.1 Nucleated Cells Administered 
 While the number of nucleated cells harvested varied by pig due to variables such as 
amount and consistency of fat, the number of nucleated cells administered did not significantly 
differ according to treatment (p > 0.34, Figure 4.1). 
4.3.2 Computed Tomography Scans 
Computed tomography scans (Figure 4.2) detail anatomical defect location in the porcine 
mandible. Defects were located in the ramus at varying levels of healing. 
4.3.3 Bone Mineral Density 
 Bone mineral density (Figure 4.3) of the defect and relative change in BMD compared to 
the original drilled bone (Figure 4.4) were significantly higher for ASCs (p = 0.032), platelet-rich 
plasma (p = 0.028), and fibrin (p = 0.036). Relative change in BMD was significantly higher for 
fibrin (p = 0.041) compared to ASCs-only. 
4.3.4 Bone Volume Fraction 
Bone volume fraction (Figure 4.5) in the defect was significantly higher for ASC (p = 
0.0039), PRP (p = 0.0011), and fibrin (p = 0.0035) treatments compared to controls (Figure 4.6). 
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Bone volume fraction of both PRP (p = 0.044) and fibrin (p = 0.016) was significantly higher 
compared to ASC-only injections. 
4.3.5 Histology 
Representative fluorescent images of bone defects injected with GFP tracer ASCs (1 
million cells per defect) displayed areas of green color representing potential cell engraftment 
within healing bone tissue (Figure 4.7). However, individual cells could not be located using 
confocal microscopy.  
Portions of mineralized bone in unstained sections appeared white while soft tissue and 
scar tissue appeared yellow in color. Organized collagen in bone stains blue with Sanderson’s 
Rapid Bone Stain while scar tissue is unstained (Figure 4.8). Mineralized tissue stains red with 
acid fuchsin counterstaining. Mineralized bone which stains blue with Rapid Bone Stain and red 
with acid fuchsin appears purple in color (Figure 4.9). 
Mineralized tissue area in the defect was significantly higher for ASC (p = 0.0037), PRP  
(p = 0.0015), and fibrin (p = 0.010) treatments compared to controls (Figure 4.10). Mineralized 
tissue area of fibrin was significantly higher compared to ASC-only injections (p = 0.048).  
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Figure 4.1: The mean number of nucleated cells administered per pig did not vary significantly 
according to treatment. Treatments with different superscripts significantly differ (p < 0.05).   
a 
a 
a 
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Figure 4.2: Representative computed tomography (CT) scans of whole mandibles with critical size 
defects. White pixels indicate high bone mineral density while black pixels indicate low density. 
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Figure 4.3: Representative dual energy X-ray absorptiometry (DXA) scans of critical size defects of 
various treatments. White pixels indicate high bone mineral density, grey is intermediate, while 
black pixels indicate low density. Mature cortical bone is indicated by black arrows. Immature 
woven bone from regeneration in the defect is indicated by blue arrows. Soft tissue is indicated by 
green arrows. 
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Figure 4.4: Bone mineral density of the defect (top) and relative change in BMD compared original 
drilled bone (bottom) was significantly higher for all three treatments using ASCs. Relative change 
in BMD was significantly higher for fibrin compared to ASC-only. Treatments with different 
superscripts significantly differ (p < 0.05).   
a 
a 
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Figure 4.5: Representative micro-computed tomography reconstructions of bone defects of various 
treatments. Yellow/orange pixels represent mineralized tissue while grey pixels indicate soft tissue. 
Mature cortical bone is indicated by black arrows. Immature woven bone from regeneration in the 
defect is indicated by blue arrows. Soft tissue is indicated by green arrows. 
 
Figure 4.6: Bone volume fraction in the defect was significantly higher  for all three cell treatments 
compared to controls. Bone volume fraction of both PRP and fibrin was significantly higher 
compared to ASC-only injections. Treatments with different superscripts significantly differ (p < 
0.05).    
a 
c, d 
b 
d 
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Figure 4.7: Representative fluorescent images of bone defects injected with GFP tracer ASCs. 
Areas of green color (black arrows)  represent potential cell engraftment within healing bone tissue. 
However, individual cells could not be located using confocal microscopy. 
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Figure 4.8: Representative histological sections with different stains. Portions of mineralized bone 
in unstained sections appear white while soft tissue and scar tissue is yellow in color. Organized 
collagen in bone stains blue with Sanderson’s Rapid Bone Stain while scar tissue is unstained. 
Mineralized tissue stains red with acid fuchsin counterstaining. Mineralized bone which stains blue 
with Rapid Bone Stain and red with acid fuchsin appears purple in color. Mature cortical bone is 
indicated by black arrows. Immature woven bone from regeneration in the defect is indicated by 
blue arrows. Soft tissue is indicated by green arrows.  
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Figure 4.9: Representative histological sections. Organized collagen in bone stains blue with 
Sanderson’s Rapid Bone Stain while scar tissue is unstained. Mineralized tissue stains red with acid 
fuchsin counterstaining. Mineralized bone which stains blue with Rapid Bone Stain and red with 
acid fuchsin appears purple in color. Mature cortical bone is indicated by black arrows. Immature 
woven bone from regeneration in the defect is indicated by blue arrows. Soft tissue is indicated by 
green arrows.   
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Figure 4.10: Mineralized tissue area in the defect was significantly higher for all three cell 
treatments compared to controls. Mineralized tissue area of fibrin was significantly higher 
compared to ASC-only injections. Treatments with different superscripts significantly differ (p < 
0.05).    
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4.4 Discussion 
The objective of this porcine animal model experiment was to compare autologous 
therapeutic options using adipose-derived stem cells alone, ASCs supplemented with platelet-
rich plasma, and ASCs encapsulated in fibrin scaffolds derived from whole blood in terms of 
new bone formation after 8 weeks. Based on the results, autologous ASCs encapsulated in fibrin 
supplemented with calcium hydrogen phosphate were determined to be the treatment which 
resulted in the most bone formation of those tested, while platelet-rich plasma treatment resulted 
in only a slight reduction in bone volume fraction (p = 0.25). These supplements to ASCs 
significantly increased bone volume fraction compared to ASCs alone (p < 0.044), indicating 
potential for improvement in adult stem cell therapies for bone defects. 
 The positive results of this study and others [7] may in part be explained by the critical-
size defect model employed. Our mandibular ramus model (Figure 4.2) maintains several 
advantages, including non-weight bearing defects, quantitative analysis, reproducibility, and low 
requirements for additional animal care. However, this model also has conditions favorable 
toward bone growth independent of treatment, including mechanical stabilization [8], defined 
bony edges with complete debridement, intactness of periosteum [9], and cyclical biomechanical 
loading due to mastication [10]. In addition, while the animals analyzed were sexually and 
skeletally mature [11], the pigs were relatively young and in good health. Despite these model 
advantages, vehicle controls treated with only DMEM resulted in bone volume fraction recovery 
of less than 10% suggesting that the 25 mm defects being utilized are critical-size defects.  
Administration of autologous ASCs aided in healing of this critical-size defect resulting 
in a defect which would eventually heal and remodel spontaneously, resulting in more than 3-
fold improvement in bone formation compared to controls (Figures 4.4, 4.6). The mechanism of 
healing is likely to be closely related to the limitations of regeneration and production of scar 
tissue of a critical-size defect. Simultaneous factors such as insufficient signaling molecules, 
neovascularization, or MSC recruitment may all play a role in the limited regenerative response 
during a critical-size defect [12]. As a heterogeneous mixture of fibroblasts, endothelial cells, 
smooth muscle cells, and other cell types, ASCs have potential to alleviate each of these 
limitations through the release of growth factors, formation of new blood vessels, and further 
recruitment of regenerative cells to the site of the defect. Though not definitive, the apparent 
77 
 
location of GFP from tracer ASCs injected at the defect site (Figure 4.7) would suggest that these 
cells are capable of differentiation and engraftment into newly forming tissue.  
However, one potential problem limiting therapeutic success of ASC administration may 
be lack of cell encapsulation at the site of the defect, if only a liquid vehicle is used. Cell 
encapsulation constricts cells and prevents their potential migration to sites other than the defect, 
reducing dilution of cell concentrations as well as the theoretical risk of tumor formation at 
ectopic sites [13]. Furthermore, bone has the potential to be better able to form in the center of 
the defect in addition to the edges, allowing healing to proceed more rapidly in multiple 
directions, eventually capable of forming bridges. Geometrically, bone formation at multiple 
sites serves to functionally reduce defect spaces and increase the size by which healing becomes 
critically limited. Therefore, due to differences in ability to encapsulate cells at the 
concentrations tested, the comparison between PRP and fibrin is imperfect, as ASCs were not 
viable at concentrations where PRP formed a stable gel (above 50%). Better cell encapsulation 
using fibrin likely explains the moderate improvement in bone formation of fibrin compared to 
PRP treatments.  
Differences in radiographic methods used in the study were noted. Dual energy X-ray 
absorptiometry (Figure 4.3) is two-dimensional method dependent in part on thickness of the 
bone sample, which varied in the pig mandibles analyzed, resulting in variation in bone mineral 
density values. Accounting for this thickness variation by normalization by the original, 
surgically removed bone reduced this discrepancy and likely improved precision of the 
measurement. In comparison, the three-dimensional method of micro-computed tomography 
(Figure 4.5) takes thickness into account and appears to be a more precise method for the circular 
ramus defect model. Based on measurements of bone mineral density and volume fraction, 
average bone mineral mass produced in the defect was estimated to range from 0.235 g for 
controls, 1.76 g for ASCs, 3.09 g for PRP, and 4.08 g for fibrin. Only 9.3 mg of calcium 
phosphate was added to fibrin scaffolds, so the contribution of exogenous CaHPO4 towards the 
bone mineral density measurement was likely to be less than 1%. While DXA and micro-CT 
have different precisions using this model, both provide useful information regarding the degree 
of bone healing in the cylindrical defect, and the results are in general agreement. 
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The approach of using fibrin scaffolds or platelet-rich plasma has several advantages, 
including rapid clinical translation, a low risk-benefit ratio, and effective improvement in bone 
formation. Nearly all materials in this prospective therapy already have Food and Drug 
Administration approval for clinical use. Use of autologous materials decreases risk of immune 
rejection, microbial contamination, and disease transmission, as well as practical, inexpensive 
collection and processing The rate of complications is expected to be less than current autograft 
methods, so this proposed treatment may eventually lead to reduced costs as well as improved 
patient outcomes.  
Both fibrin and PRP treatments have minor drawbacks. The drawing of non-clotted blood 
requires rapid processing and is vulnerable to syringe blockage. Excess fibrin has also been 
associated with the formation of scar tissue [14,15], some of which was observed during sample 
collection. In the craniofacial region, this scar tissue may result in reduced patient satisfaction. In 
the case of PRP, the pro-inflammatory component of the released platelet factors results in more 
pain and swelling than a standard surgery for several days post-surgery. This additional swelling 
may require thicker, stronger sutures to stay within breaking strength which may result in larger 
scars at the incision site. Generally, the benefits of improved bone formation in these treatments 
derived from autologous sources may be worth the risks and drawbacks posed.  
Future work to improve these autologous therapies may include the substitution of 
autologous bone dust or chips in place of calcium phosphate [16]. Besides being a more 
autologous approach, bone chips harvested during the surgical removal of bone maintain lacunae 
which house osteocytes that remain viable if collected and re-implanted within the timeframe of 
a standard bone graft surgery. Furthermore, bone chips contain remnants of trabecular 
architecture capable of infiltration by newly forming blood vessels, compared to calcium 
phosphate granules which are generally internally solid and impenetrable. Improvements in PRP 
processing to improve ASC viability at higher concentrations may improve bone formation, as 
the biological adhesive properties of gelled PRP may improve bone grafting. Osmotic balancing 
along with fine-tuning of anticoagulant:calcium ratios may result in cell viability suitable for 
ASC administration. Further studies using more clinically-relevant bone defects, such as 
calvarial, mandibular segmental, or femoral traction defects [17,18], among others, or using pigs 
in states of compromised bone healing, such as diabetes [19] or older in age, are warranted. 
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Because the autologous materials studied in this dissertation cannot bear significant loads, a 
much stiffer scaffold and/or other methods of stabilization would be required for body weight-
bearing applications. We conclude that addition of autologous blood products, either 20% 
platelet-rich plasma or fibrin scaffolds derived from whole blood supplemented with calcium 
phosphate, to adipose-derived stem cells derived from lipoaspirate, may be advantageous due to 
improved bone formation without requiring harvesting of patient bone. In summary, the present 
study demonstrates the potential for improvement in cell therapies towards an autologous bone 
tissue construct for craniofacial bone repair.  
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CHAPTER 5                                                                                                                       
SUMMARY AND CONCLUSIONS 
 
This dissertation evaluated the effectiveness of autologous therapies for bone 
reconstruction in the mandible using the Yorkshire pig as a preclinical animal model. The tissue 
engineering approach of scaffolds, growth factors and stem cells were sourced from autologous 
blood and fat from liposuction. Modifications of fibrin scaffolds were evaluated in terms of 
coagulation speed, degradation, surface roughness, stiffness, and osteogenesis. Platelet-rich 
plasma concentrations were assessed for proliferation, migration, and velocity of cell spreading. 
In a 25-mm critical-size defect, treatments of fibrin scaffolds supplemented with calcium 
hydrogen phosphate or 20% platelet-rich plasma combined with autologous adipose-derived 
stem cells were compared with adipose-derived stem cells alone and untreated controls over an 8 
week time point. Bone formation was assessed using dual-energy X-ray absorptiometry, micro-
computed tomography, and histology. 
 Results included improved stiffness, coagulation speed, and surface roughness in fibrin 
scaffolds supplemented with calcium phosphate. A platelet-rich plasma concentration of 20% 
promoted increased adipose-derived stem cell proliferation, increased migration, as well as 
increased cell velocity. These results prompted the selection of calcium phosphate-supplemented 
fibrin and 20% platelet-rich plasma for the subsequent in vivo study. These treatments resulted in 
improved bone formation in a 25-mm porcine mandibular defect model compared to 
administration of ASCs alone. All treatments with ASCs resulted in significantly more bone 
formation than untreated controls. For untreated controls, ASCs only, or ASCs with platelet-rich 
plasma, bone formation was observed to proceed from the outside towards the center similar to 
the natural healing process. For ASCs with fibrin, bone formation was observed throughout the 
defect, including the center, due to likely cell encapsulation and viable cells. Tracer GFP cells 
were observed, indicating that these ASCs graft successfully in forming tissue and participate in 
healing in part by differentiation into cell types which either support or form new bone tissue. 
For the assessment of bone formation, micro-computed tomography appeared to be a more 
precise measurement than dual energy X-ray tomography. In summary, addition of autologous 
blood treatments further improved bone healing in a critical-size defect model (Figure 5.1). 
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 Future studies should examine the use of these autologous bone tissue engineering 
materials in more clinically-relevant defects, such as calvarial, mandibular segmental, or femoral 
traction. The mechanism of adipose-derived stem cell attachment to fibrin scaffolds, including 
molecules and physical characteristics required, would aid in improving scaffold design. 
Addition of autologous bone chips acquired during the surgical procedure may improve results 
over calcium phosphate granules. Efforts to increase cell viability at higher platelet-rich plasma 
concentrations and its subsequent gelation may provide added benefits of cell encapsulation. 
Stiffer scaffolds such as autologous bone, hydroxyapatite or poly-caprolactone, which are able to 
bear body weight, will be required for successful treatment of the majority of bone defects. In 
addition, combining fibrin scaffolds with platelet-rich plasma may result in synergistic 
improvement above each component separately and would comprise a complete tissue 
engineering construct. While more study is needed, this autologous approach has potential to 
present a viable alternative to current bone grafting methods. 
 Analytical methods used in this study focused primarily on digital image analysis, which 
has limitations of image resolution and subjectivity of the observer. Despite these limitations, 
image analysis remains a highly flexible, adaptable method able to measure high volumes of 
information for a wide range of applications, as demonstrated in this dissertation. Efforts in 
automation would result in higher-throughput measurements with reduced subjectivity. Because 
metrics are essential for evaluation of the suitability of bone tissue engineering scaffolds, image 
analysis will remain one of key methods for quantitative, reproducible assessment. Some 
measurements developed in this dissertation may have potential to be utilized for evaluation of 
other prospective bone tissue engineering treatments or perhaps for clinical assessment of bone 
grafting. 
 The approach detailed in this dissertation has several advantages, including rapid clinical 
translation, a low risk-benefit ratio, and effective improvement in bone formation. Nearly all 
materials in this prospective therapy already have Food and Drug Administration approval for 
clinical use. Use of autologous materials decreases risk of immune rejection, microbial 
contamination, and disease transmission, as well as practical, inexpensive collection and 
processing. One clinical drawback to this procedure could be the multi-disciplinary cooperation 
required due to simultaneous liposuction and bone grafting in one procedure, which may 
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contribute to increased cost in the short-term. However, the rate of complications is expected to 
be less than current autograft methods, so this proposed autologous treatment may eventually 
lead to reduced costs as well as improved patient outcomes. We conclude that addition of 
autologous blood products, either 20% platelet-rich plasma or fibrin scaffolds derived from 
whole blood supplemented with calcium phosphate, to adipose-derived stem cells derived from 
lipoaspirate, may be advantageous due to improved bone formation without requiring harvesting 
of patient bone. The studies in this dissertation represent a small, but significant step towards an 
autologous bone tissue engineering construct for craniofacial bone repair. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Proposed model for beneficial effects of platelet-rich plasma and fibrin for adipose-
derived stem cell therapy for critical-size bone defects.  
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APPENDIX A                                                                                                           
PROTOCOLS 
A.1 Liposuction 
The following protocol assumes you are using a 15 cm cannula and are attempting to retrieve 
300-450 mL of aspirate. 
1. Shave approximately 0.75 meters in length and 0.6 meters in diameter from the back side 
of the pig. 
2. Clean area from the center outward in a spiraling motion first using 70% Ethanol, then 
betadine solution. (repeat 3 times) 
3. Apply a layer of Zephiran, (cover with gauze pads soaked in zephiran until ready to begin 
liposuction) 
4. Choose 6 spots approximately 6 inches from each other within the clean area to penetrate 
the pig. 
5. In the first spot using a trocar (chisel with sharp point) approximately 1cm in diameter 
(diameter should be slightly wider than the width of cannula) place chisel at 90 degree 
angle to “catch” skin. Then maintain pressure on the skin while turning the chisel as close 
to 180 degrees along the length side of the back away from a previously agitated area.  
Hammer the chisel in far enough to stretch the hole to be the bulk of the width of the 
trocar (chisel). 
6. Remove trocar (chisel). 
7. Using a 60mL syringe with a cannula attached fill the syringe with 20mL of saline with 
epinephrine (1 mg per liter, 1:1,000,000). 
8. Insert the cannula into the hole at an angle as close to 180 degrees along the pigs back 
side as possible. 
9. Use a back and forth motion to agitate the fat cells while slowly and gradually releasing 
the saline with epinephrine (to reduce bleeding). 
10. Remove the syringe with cannula. 
11. Using suction with a large insert and collect all tissue agitated by the canula during the 
previous step. 
12. When no tissue (cells) is visibly being collected by suction, remove suction. 
13. Repeat steps 7-12 for same location about 4-5 times or until limited fat is being collected. 
Then start a new location. 
14. Using your 5 other chosen points for penetration repeat steps 5-12. 
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A.2 Adipose Derived Stem Cell Isolation Using Lipoaspirate 
The protocol assumes that the volume of the aspirate obtained from liposuction is 300ml.  
1. Aspirate obtained from liposuction is typically ~300ml  divide and transfer 100ml of 
aspirate into 250ml tubes (3 tubes if total volume was 300ml) 
2. Add 300ml PBS to the original container (so that aspirate:DPBS is 1:1) 
3. Add 225mg of collagenase to 300ml PBS (so that you have 75mg collagenase/100ml 
PBS) and mix well 
4. Divide and transfer 100ml of the PBS with collagenase mixture to the three 250ml tubes 
(so that they have a total of 200ml now) 
5. Place the three 250ml flasks on the orbital shaker that is inside the 370C incubator  30 
mins 
6. Centrifuge @ 1400rpm (547 xg, the centrifuge on the floor of the lab) for 10 mins 
7. Remove tubes from the centrifuge  there will be a floating fat pellet at the top and a 
cell pellet at the bottom. Pass a 10ml pipette along the wall, through the floating fat, and 
aspirate out the cells at the bottom and transfer them to 50ml falcon tubes. Repeat until 
all cells are removed. 
8. Centrifuge 50ml falcon tubes @1400 rpm for 5 mins 
9. Remove supernatant using 10ml pipette  remove as much as possible, but take care not 
to remove the cells on the surface of the pellet 
10. Add 2ml EL buffer (erythrocyte lysis buffer) to each tube  mix gently by hand for ~ 
2mins 
11. Add PBS to make the final volume ~45-50ml (still working with the same 50ml falcon 
tubes) 
12. Centrifuge @1400rpm for 5 mins 
13. Remove supernatant and resuspend the pellet in one of the 50ml falcon tubes in 10ml 
DMEM  mix well and transfer it to the 2nd tube containing the cell pellet  mix well 
and transfer everything to the 3rd tube containing the cell pellet 
14. Filter DMEM/cell suspension using strainer 
15. Centrifuge filtrate @1400rpm for 5 mins  remove supernatant so that you have the 
right volume for transplanting 
 
